ATE378403T1 - Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern - Google Patents

Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern

Info

Publication number
ATE378403T1
ATE378403T1 AT01987182T AT01987182T ATE378403T1 AT E378403 T1 ATE378403 T1 AT E378403T1 AT 01987182 T AT01987182 T AT 01987182T AT 01987182 T AT01987182 T AT 01987182T AT E378403 T1 ATE378403 T1 AT E378403T1
Authority
AT
Austria
Prior art keywords
transchromosomal
producing human
human antibodies
transgenic rodents
producing
Prior art date
Application number
AT01987182T
Other languages
English (en)
Inventor
Kazuma Tomizuka
Isao Ishida
Nils Lonberg
Ed Halk
Original Assignee
Medarex Inc
Kirin Brewery
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medarex Inc, Kirin Brewery filed Critical Medarex Inc
Application granted granted Critical
Publication of ATE378403T1 publication Critical patent/ATE378403T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Humanized animals, e.g. knockin
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/02—Breeding vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knockout animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/30—Animal model comprising expression system for selective cell killing, e.g. toxins, enzyme dependent prodrug therapy using ganciclovir
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
AT01987182T 2000-11-30 2001-11-30 Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern ATE378403T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25034000P 2000-11-30 2000-11-30

Publications (1)

Publication Number Publication Date
ATE378403T1 true ATE378403T1 (de) 2007-11-15

Family

ID=22947322

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01987182T ATE378403T1 (de) 2000-11-30 2001-11-30 Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern

Country Status (17)

Country Link
US (6) US7041870B2 (de)
EP (2) EP1916303B1 (de)
JP (1) JP3523245B1 (de)
KR (1) KR100857943B1 (de)
CN (2) CN101940189A (de)
AT (1) ATE378403T1 (de)
AU (2) AU2002239422B2 (de)
CA (1) CA2430013C (de)
DE (1) DE60131456T2 (de)
DK (1) DK1354034T3 (de)
ES (2) ES2405944T3 (de)
HK (1) HK1064708A1 (de)
IL (2) IL155977A0 (de)
MX (1) MXPA03004793A (de)
PT (1) PT1354034E (de)
TW (1) TWI313299B (de)
WO (1) WO2002043478A2 (de)

Families Citing this family (1004)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US20060293266A1 (en) * 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7393652B2 (en) * 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
CN100387713C (zh) 2000-08-11 2008-05-14 麒麟医药株式会社 调节磷酸代谢,钙代谢,钙化和维生素d代谢的多肽及其编码dna
US7041870B2 (en) 2000-11-30 2006-05-09 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
WO2002076401A2 (en) 2001-03-26 2002-10-03 Dana-Farber Cancer Institute, Inc. Method of attenuating reactions to skin irritants
AU2002309063B8 (en) * 2001-05-11 2008-04-24 Kyowa Kirin Co., Ltd. Artificial human chromosome containing human antibody lambda light chain gene
US7923012B2 (en) 2001-12-28 2011-04-12 Kyowa Hakko Kirin Co., Ltd. Antibody against fibroblast growth factor-23
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
SI1523496T1 (sl) 2002-07-18 2011-11-30 Merus B V Rekombinantno proizvajanje zmesi protiteles
JP2005537805A (ja) * 2002-09-09 2005-12-15 カリフォルニア インスティチュート オブ テクノロジー ヒト化マウスを作成するための方法および組成物
NZ568769A (en) 2002-10-17 2010-04-30 Genmab As Human monoclonal antibodies against CD20
US7544678B2 (en) * 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
EP1572106B1 (de) 2002-11-15 2010-05-05 Novartis Vaccines and Diagnostics, Inc. Methoden zur verhinderung und behandlung von krebs-metastasierung und mit krebs-metastasierung einhergehendem knochenverlust
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
JP2006520610A (ja) * 2003-03-04 2006-09-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド ハイブリッド不変領域を産生するのに用いるベクター
CN1832965B (zh) 2003-03-04 2011-03-02 麒麟麦酒株式会社 内皮细胞特异性抗体及其用途
JPWO2004083425A1 (ja) * 2003-03-17 2006-06-22 麒麟麦酒株式会社 歯周病治療剤
SG173919A1 (en) 2003-04-23 2011-09-29 Medarex Inc Compositions and methods for the therapy of inflammatory bowel disease
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
US7465446B2 (en) 2003-05-30 2008-12-16 Medarex, Inc. Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP1645183B1 (de) * 2003-06-16 2013-03-13 Kyushu University, National University Corporation Verfahren zur herstellung von immunkompetenten zellen menschlichen ursprungs
US7642341B2 (en) 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
EP1533617A1 (de) 2003-11-19 2005-05-25 RMF Dictagene S.A. Angiogenese inhibierende Moleküle, deren Auswahl, Herstellung und Benutzung zur Behandlung und Diagnose von Krebs
US7741449B2 (en) 2003-12-10 2010-06-22 Medarex, Inc. Anti-interferon alpha antibodies
CN102838675B (zh) 2003-12-10 2014-07-30 梅达雷克斯有限责任公司 Ip-10抗体及其用途
PT2311873T (pt) 2004-01-07 2018-11-20 Novartis Vaccines & Diagnostics Inc Anticorpo monoclonal específico para m-csf e respetivos usos
DK1737971T3 (da) 2004-01-20 2017-11-13 Merus Nv Blandinger af bindingsproteiner
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
EP1786463A4 (de) * 2004-03-26 2009-05-20 Human Genome Sciences Inc Antikörper gegen nogo-rezeptor
CA2561533C (en) 2004-04-13 2015-06-16 Yvo Graus Anti-p-selectin antibodies
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP2583981A3 (de) 2004-05-28 2013-07-31 Agensys, Inc. An PSCA-Proteine bindende Antikörper und zugehörige Moleküle
CA2570823C (en) 2004-06-21 2015-02-24 Medarex, Inc. Interferon alpha receptor 1 antibodies and their uses
KR100918746B1 (ko) 2004-09-06 2009-09-24 교와 핫꼬 기린 가부시키가이샤 항 ａ３３ 항체
US7432359B2 (en) 2004-09-06 2008-10-07 Kirin Pharma Kabushiki Kaisha Anti-A33 antibody
AU2005310247A1 (en) 2004-11-02 2006-06-08 The Board Of Trustees Of The Leland Stanford Junior University Methods for inhibition of NKT cells
US8124091B2 (en) 2004-12-06 2012-02-28 Kyowa Hakko Kirin Co., Ltd. Human monoclonal antibodies to influenza M2 protein and methods of making and using same
US7906625B2 (en) * 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
EP2551282A3 (de) 2005-03-23 2013-02-13 Genmab A/S Antikörper gegen CD38 zur Behandling von multiplem Myelom
AU2006230563B8 (en) 2005-03-31 2010-06-17 Agensys, Inc. Antibodies and related molecules that bind to 161P2F10B proteins
US20090041783A1 (en) 2005-04-28 2009-02-12 Mochida Pharmaceutical Co., Ltd. Anti-platelet membrane glycoprotein vi monoclonal antibody
DK2161336T4 (en) 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
AU2006249087B2 (en) 2005-05-20 2012-05-17 Lonza Biologics Plc High-level expression of recombinant antibody in a mammalian host cell
AU2006265108C1 (en) 2005-07-01 2013-01-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
EP1913028B1 (de) * 2005-07-28 2015-03-04 Novartis AG Anwendung von antikörpern gegen m-csf
JP5457671B2 (ja) * 2005-07-28 2014-04-02 ノバルティス アーゲー Ｍ−ｃｓｆ特異的モノクローナル抗体およびその使用
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
EP1762575A1 (de) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identifizierung Tumor-assoziierter Antigene für Diagnoseund Therapie
JP2009508494A (ja) 2005-09-16 2009-03-05 ラプトール ファーマシューティカル インコーポレイテッド Ｃｒを含むタンパク質に対して特異的な受容体−結合タンパク質（ｒａｐ）変異体を含む組成物およびその使用
EP1934261B1 (de) * 2005-09-26 2014-10-29 Medarex, L.L.C. Humane monoklonale antikörper gegen cd70
AU2006294554B2 (en) 2005-09-26 2013-03-21 E. R. Squibb & Sons, L.L.C. Antibody-drug conjugates and methods of use
US9068200B2 (en) 2005-10-05 2015-06-30 Universita' Degli Studi Milano-Bicocca Method for the transfer of episomal vectors into animal cells
JP5006330B2 (ja) 2005-10-21 2012-08-22 ノバルティス アーゲー Ｉｌ１３に対するヒト抗体および治療的使用
EP1790664A1 (de) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoklonale Antikörper gegen Claudin-18 zur Behandlung von Krebs
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
NZ568015A (en) 2005-12-08 2012-03-30 Medarex Inc Human monoclonal antibodies to O8E
CN103204931B (zh) 2005-12-08 2016-08-03 米德列斯公司 抗岩藻糖基-gm1的人单克隆抗体及使用抗岩藻糖基-gm1抗体的方法
EP1976883B1 (de) 2006-01-17 2012-10-03 Medarex, Inc. Monoklonale antikörper gegen cd30 ohne fucosyl- und xylosylreste
GB0603683D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
US8278421B2 (en) 2006-03-20 2012-10-02 Xoma Techolology Ltd. Human antibodies specific for gastrin materials and methods
CN101415730B (zh) 2006-03-30 2013-04-10 诺瓦提斯公司 c-Met抗体的组合物和使用方法
EP2003960B1 (de) 2006-03-31 2015-06-10 E. R. Squibb & Sons, L.L.C. Chimäre antikörper exprimierende transgene tiere für die zubereitung humaner antikörper
TWI390034B (zh) 2006-04-06 2013-03-21 Kyowa Hakko Kirin Co Ltd Novel anti-CD98 antibody
CA2656620C (en) 2006-07-04 2018-03-13 Genmab A/S Cd20 binding molecules for the treatment of copd
WO2008011571A1 (en) * 2006-07-21 2008-01-24 Amgen Inc. Polypeptides with reduced susceptibility to oxidation and methods of making
ES2613957T3 (es) 2006-08-04 2017-05-29 Medimmune Limited Anticuerpos contra ERBB2
CN101626783A (zh) * 2006-08-04 2010-01-13 诺华有限公司 Ephb3-特异性抗体和其应用
TW200817437A (en) 2006-08-11 2008-04-16 Medarex Inc Monoclonal antibodies against stromal cell derived factor-1 (SDF-1)
EP3415532A1 (de) 2006-08-18 2018-12-19 XOMA Technology Ltd. Prlr-spezifischer antikörper und verwendungen davon
BRPI0716088B8 (pt) 2006-08-28 2021-05-25 Kyowa Hakko Kirin Co Ltd anticorpo isolado, composição, molécula de ácido nucléico isolada, vetor, método para produzir um anticorpo, hibridoma, e, kit
EP2074144A4 (de) 2006-09-05 2011-03-16 Medarex Inc Antikörper gegen knochenmorphogene proteine und rezeptoren dafür und verfahren zu ihrer anwendung
US20080132688A1 (en) * 2006-09-22 2008-06-05 Amgen Inc. Methods for Removing Viral Contaminants During Protein Purification
DK2081595T3 (da) 2006-09-26 2019-07-15 Genmab As Anti-cd38 plus corticosteroid plus et ikke-corticosteroid kemoterapeutikum til behandling af tumorer
EP2068928A2 (de) 2006-09-28 2009-06-17 Merck Serono SA Junctional adhesion molecule-c (jam-c) bindende verbindungen und anwendungsverfahren davon
PL2486941T3 (pl) 2006-10-02 2017-08-31 E. R. Squibb & Sons, L.L.C. Przeciwciała ludzkie wiążące cxcr4 i ich wykorzystanie
US8613925B2 (en) 2006-10-19 2013-12-24 Csl Limited Anti-IL-13Rα1 antibodies and their uses thereof
US20110076279A1 (en) * 2006-10-20 2011-03-31 Schering Corporation Fully human anti-vegf antibodies and methods of using
US7846434B2 (en) 2006-10-24 2010-12-07 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
BRPI0717601A2 (pt) * 2006-10-24 2013-10-22 Trubion Pharmaceuticals Inc Materiais e métodos para imunoglicoproteínas melhoradas
MX2009005189A (es) 2006-11-15 2009-06-30 Medarex Inc Anticuerpos humanos monoclonales para btla y metodos de uso.
TWI447124B (zh) 2006-12-01 2014-08-01 Medarex Llc 結合ｃｄ２２的人類抗體與其應用
WO2008070780A1 (en) 2006-12-07 2008-06-12 Novartis Ag Antagonist antibodies against ephb3
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
KR20090088946A (ko) 2006-12-14 2009-08-20 메다렉스, 인코포레이티드 씨디70에 결합하는 인간 항체 및 이의 용도
JP5645409B2 (ja) 2006-12-20 2014-12-24 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー ＩＬ−１β関連疾患の治療方法
US20080214987A1 (en) 2006-12-22 2008-09-04 Nanomed Devices, Inc. Microdevice And Method For Transdermal Delivery And Sampling Of Active Substances
TW201307390A (zh) 2007-02-02 2013-02-16 Amgen Inc 海帕西啶（ｈｅｐｃｉｄｉｎ）、海帕西啶拮抗劑及使用方法
US7883705B2 (en) 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same
SG178789A1 (en) 2007-02-16 2012-03-29 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
EP1970384A1 (de) 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoklonale Antikörper zur Krebsbehandlung
NZ614857A (en) 2007-03-29 2015-04-24 Genmab As Bispecific antibodies and methods for production thereof
EP1997832A1 (de) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoklonale Antikörper gegen Claudin-18 zur Behandlung von Krebs
US20100267934A1 (en) 2007-05-31 2010-10-21 Genmab A/S Stable igg4 antibodies
EP2167669A2 (de) 2007-05-31 2010-03-31 Genmab A/S Monovalente menschliche antikörper produzierende transgene tiere und aus diesen tieren isolierbare antikörper
DK2336329T3 (da) 2007-06-01 2013-01-07 Omt Inc Sammensætninger og fremgangsmåder til hæmning af endogene immunglobulingener og til produktion af transgene, humane, idiotypiske antistoffer
US9693539B2 (en) 2007-08-10 2017-07-04 E. R. Squibb & Sons, L.L.C. HCO32 and HCO27 and related examples
WO2009026274A1 (en) 2007-08-22 2009-02-26 Medarex, Inc. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
DK2769729T3 (en) 2007-09-04 2019-04-23 Compugen Ltd POLYPEPTIDES AND POLYNUCLEOTIDES AND APPLICATIONS THEREOF AS A PHARMACEUTICAL OBJECTIVE FOR THE PRODUCTION OF MEDICINAL PRODUCTS AND BIOTECHNOLOGICAL PRODUCTS
EP3750554A3 (de) 2007-09-18 2021-07-28 La Jolla Institute for Allergy and Immunology Light-inhibitoren zur behandlung von asthma, lungen- und atemwegsentzündungen sowie respiratorischen, interstitiellen, pulmonaren und fibrotischen krankheiten
MX342551B (es) 2007-09-26 2016-10-04 Chugai Pharmaceutical Co Ltd Region constante de anticuerpo modificada.
AU2008304111B2 (en) 2007-09-27 2014-04-24 Amgen Inc. Pharmaceutical formulations
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
EP2214706A1 (de) 2007-10-23 2010-08-11 Novartis AG Verwendung von trkb-antikörpern zur behandlung von atemwegserkrankungen
EP2567709B1 (de) 2007-11-02 2017-12-27 Novartis AG Moleküle und Verfahren zum Modulieren eines Lipoproteinrezeptor-assoziierten Proteins 6 (LRP6) mit geringer Dichte
CA2705841C (en) * 2007-11-14 2015-01-27 National University Corporation Tottori University Mammalian artificial chromosome vector comprising human cytochrome p450 gene (cluster) and non-human mammalian animal retaining the same
ES2962777T3 (es) 2007-11-15 2024-03-21 Amgen Inc Formulación acuosa de anticuerpos estabilizada por antioxidantes para la administración parenteral
CN110698561A (zh) 2007-12-14 2020-01-17 诺沃—诺迪斯克有限公司 抗人nkg2d抗体及其用途
SI2242771T1 (sl) 2007-12-14 2013-09-30 Bristol-Myers Squibb Company Vezane molekule k humanemu ox40 receptorju
PL2391650T3 (pl) 2007-12-20 2015-03-31 Xoma Us Llc Sposoby leczenia dny
US8414893B2 (en) 2007-12-21 2013-04-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
NZ587506A (en) 2008-01-25 2012-09-28 Univ Aarhus Selective exosite inhibition of papp-a activity against igfbp-4
JP5701064B2 (ja) 2008-01-25 2015-04-15 アムジエン・インコーポレーテツド フェロポーチン抗体およびその使用方法
US8263073B2 (en) 2008-02-04 2012-09-11 Medarex, Inc. Anti-CTLA-4 antibodies with reduced blocking of binding of CTLA-4 to B7 and uses thereof
BRPI0906387A2 (pt) 2008-02-05 2015-07-07 Bristol Myers Squibb Co Anticorpos alfa 5 - beta 1 e seus usos
US9441034B2 (en) 2008-03-27 2016-09-13 Zymogenetics, Inc. Compositions and methods for inhibiting PDGFRβ and VEGF-A
SG2014014138A (en) * 2008-03-31 2014-07-30 Genentech Inc Compositions and methods for treating and diagnosing asthma
US9315577B2 (en) 2008-05-01 2016-04-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
MX345395B (es) * 2008-06-25 2017-01-30 Esbatech Alcon Biomed Res Unit Humanizacion de anticuerpos de conejos usando una estructura de anticuerpos universal.
ES2502940T3 (es) 2008-08-05 2014-10-06 Toray Industries, Inc. Composición farmacéutica para el tratamiento y la prevención del cáncer
MY159396A (en) 2008-08-05 2016-12-30 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
MX2011001409A (es) 2008-08-14 2011-03-29 Cephalon Australia Pty Ltd Anticuerpos anti-il-12/il-23.
CN102282172B (zh) 2008-09-07 2014-02-19 台湾醣联生技医药股份有限公司 抗伸展的ⅰ型鞘糖脂抗体、其衍生物以及用途
US8703129B2 (en) 2008-09-07 2014-04-22 GlycoNex, Inc. Antibodies against extended type 1 chain antigens, derivatives thereof and use
EP2166021A1 (de) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoklonale Antikörper zur Krebsbehandlung
EP3530672B1 (de) 2008-09-26 2024-05-01 Dana-Farber Cancer Institute, Inc. Menschliche anti-pd1-, pd-l1- und pd-l2-antikörper und verwendungen davon
US20110237514A1 (en) 2008-09-30 2011-09-29 Kyowa Hakko Kirin Co., Ltd. PHARMACEUTICAL COMPOSITION FOR TREATING BONE DISEASES WHICH COMPRISES PROTEIN COMPRISING Frizzled1, Frizzled2 OR Frizzled7 EXTRACELLULAR CYSTEINE-RICH DOMAIN
KR101826224B1 (ko) 2008-09-30 2018-02-06 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 인간 이외의 포유동물
WO2010038610A1 (ja) 2008-09-30 2010-04-08 オリエンタル酵母工業株式会社 新しい軟骨細胞増殖及び分化誘導剤
US20100124741A1 (en) * 2008-11-18 2010-05-20 Quest Disgnostics Investments Incorporated METHODS FOR DETECTING IgH/BCL-1 CHROMOSOMAL TRANSLOCATION
WO2010063785A2 (en) 2008-12-03 2010-06-10 Genmab A/S Antibody variants having modifications in the constant region
EP2865689A1 (de) 2008-12-08 2015-04-29 Compugen Ltd. FAM26F Polypeptide und Polynukleotide und Verwendungen davon als Arzneimittel-Target zur Herstellung von Arzneimitteln und Biologika
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
SG10201708690SA (en) 2008-12-09 2017-12-28 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
HRP20231525T1 (hr) 2009-02-20 2024-03-15 Astellas Pharma Inc. Postupci i pripravci za dijagnozu i liječenje raka
MX2011007049A (es) 2009-02-24 2011-08-03 Esbatech Alcon Biomed Res Unit Metodos para identificar inmunoligadores de los antegenos de la superficie celular.
MX2011009220A (es) 2009-03-05 2011-09-28 Medarex Inc Anticuerpos completamente humanos especificos para la molecula de adhesion celular 1.
JP2012521197A (ja) 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド 担体免疫グロブリンおよびその使用
US8124740B2 (en) 2009-03-25 2012-02-28 Genentech, Inc. Anti- α5 β1 antibodies and uses thereof
WO2010112034A2 (en) 2009-04-02 2010-10-07 Aarhus Universitet Compositions and methods for treatment and diagnosis of synucleinopathies
WO2010117325A1 (en) 2009-04-08 2010-10-14 Olle Hernell New methods for treatment of inflammatory diseases
US8647623B2 (en) 2009-04-10 2014-02-11 Kyowa Hakko Kirin Co., Ltd Method for treatment of blood tumor using anti-TIM-3 antibody
EA030182B1 (ru) 2009-04-20 2018-07-31 Оксфорд Байотерепьютикс Лтд. Антитела, специфические для кадгерина-17
WO2010124113A1 (en) 2009-04-23 2010-10-28 Infinity Pharmaceuticals, Inc. Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
CN102459342B (zh) 2009-04-27 2015-01-07 协和发酵麒麟株式会社 用于治疗血液肿瘤的抗il-3ra抗体
EP3275900A1 (de) 2009-04-27 2018-01-31 Novartis AG Zusammensetzungen und verfahren zur förderung des muskelwachstums
EP2424894A1 (de) 2009-04-27 2012-03-07 Novartis AG Zusammensetzungen und verfahhren zur anwendung von für die beta1-untereinheit des il-12-rezeptors spezifischen antikörpern
ES2514319T3 (es) 2009-05-04 2014-10-28 Abbvie Research B.V. Anticuerpos contra el factor de crecimiento nervioso (NGF) con estabilidad in vivo mejorada
EP2445925A1 (de) 2009-06-25 2012-05-02 Bristol-Myers Squibb Company Proteinaufreinigung mittels präzipitation von caprylsäure (octansäure)
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
DK2564695T3 (en) 2009-07-08 2015-05-26 Kymab Ltd Animal models and therapeutic molecules
US20120204278A1 (en) 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
WO2011019844A1 (en) 2009-08-13 2011-02-17 Crystal Bioscience Inc. Transgenic animal for production of antibodies having minimal cdrs
WO2011021146A1 (en) 2009-08-20 2011-02-24 Pfizer Inc. Osteopontin antibodies
WO2011029823A1 (en) 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
US20120178910A1 (en) 2009-09-23 2012-07-12 Medarex, Inc. Cation exchange chromatography (methods)
EP2480888B1 (de) 2009-09-25 2016-11-30 XOMA Technology Ltd. Screening-verfahren
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
US20120231004A1 (en) 2009-10-13 2012-09-13 Oxford Biotherapeutic Ltd. Antibodies
EP2493506B1 (de) 2009-10-30 2019-04-10 Janssen Biotech, Inc. Il-17a-antagonisten
EP2322555A1 (de) 2009-11-11 2011-05-18 Ganymed Pharmaceuticals AG Antikörper spezifisch für Claudin 6 (CLDN6)
EP3689911A1 (de) 2009-11-11 2020-08-05 Ganymed Pharmaceuticals GmbH Für claudin 6 (cldn6) spezifische antikörper
NO2501822T3 (de) 2009-11-17 2018-01-13
CA2781532A1 (en) 2009-11-20 2011-05-26 Amgen Inc. Anti-orai1 antigen binding protein that binds the second extracellular loop of orai1
US9428586B2 (en) 2009-12-01 2016-08-30 Compugen Ltd Heparanase splice variant
US8865462B2 (en) * 2010-01-20 2014-10-21 Crystal Bioscience Inc. Sustained culture of avian gonocytes
PL2532743T3 (pl) 2010-02-04 2015-09-30 Toray Industries Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka
US8709418B2 (en) 2010-02-04 2014-04-29 Toray Industries, Inc. Pharmaceutical composition for treating CAPRIN-1 expressing cancer
AU2011211682B2 (en) 2010-02-04 2015-08-13 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
KR101801667B1 (ko) 2010-02-04 2017-11-27 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
ES2583627T3 (es) 2010-02-04 2016-09-21 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la prevención del cáncer
US8609092B2 (en) 2010-02-08 2013-12-17 Agensys, Inc. Antibody drug conjugates (ADC) that bind to 161P2F10B proteins
WO2011101328A2 (en) 2010-02-18 2011-08-25 Roche Glycart Ag Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor
MX2012008958A (es) 2010-02-18 2012-08-23 Genentech Inc Antagonista de neurogulina y usos de los mismos para el tratamiento contra el cancer.
US20130004516A1 (en) 2010-03-04 2013-01-03 Dainippon Sumitomo Pharma Co., Ltd. Drug for inflammatory bowel disease
CN103003307B (zh) 2010-03-10 2017-08-11 根马布股份公司 抗c‑MEt的单克隆抗体
NZ602054A (en) 2010-03-17 2014-10-31 Abbott Res Bv Anti-nerve growth factor (ngf) antibody compositions
EP2371864A1 (de) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoklonale Antikörper zur Krebsbehandlung
BR112012022044A2 (pt) 2010-03-24 2020-08-25 Genentech Inc ''anticorpo,imunoconjugado,formulação farmacêutica,uso do anticorpo,método de tratamento,anticorpo biespecifico isolado e célula hospedeira''.
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
CN103119054B (zh) 2010-03-26 2017-01-18 达特茅斯大学理事会 Vista调节性t细胞介体蛋白、vista结合剂及其用途
EP3248462B1 (de) 2010-03-31 2024-03-13 Ablexis, LLC Gentechnische herstellung von mäusen zur herstellung von chimären antikörpern
PL2563813T3 (pl) 2010-04-30 2016-01-29 Alexion Pharma Inc Przeciwciała anty-C5a i sposoby stosowania przeciwciał
WO2011140151A1 (en) 2010-05-04 2011-11-10 Dyax Corp. Antibodies against epidermal growth factor receptor (egfr)
WO2011140254A1 (en) 2010-05-04 2011-11-10 Adimab, Llc Antibodies against epidermal growth factor receptor (egfr) and uses thereof
CA2798390A1 (en) 2010-05-06 2011-11-10 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
SG185416A1 (en) 2010-05-06 2012-12-28 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
EP2575880B1 (de) 2010-05-27 2019-01-16 Genmab A/S Monoklonale antikörper gegen her2-epitop
CA2800785C (en) 2010-05-27 2019-09-24 Genmab A/S Monoclonal antibodies against her2
WO2011152503A1 (ja) 2010-06-02 2011-12-08 大日本住友製薬株式会社 自己免疫疾患またはアレルギー疾患の治療剤
DK2580243T3 (da) 2010-06-09 2020-01-13 Genmab As Antibodies against human cd38
RS56599B1 (sr) 2010-06-15 2018-02-28 Genmab As Konjugati humanog antitela sa lekom protiv tkivnog faktora
CN103080136B (zh) 2010-06-18 2015-08-12 霍夫曼-拉罗奇有限公司 抗Axl抗体及使用方法
CN104404050B (zh) * 2010-06-22 2018-06-08 瑞泽恩制药公司 杂交轻链小鼠
WO2011163401A2 (en) 2010-06-22 2011-12-29 Neogenix Oncology, Inc. Colon and pancreas cancer specific antigens and antibodies
EP2404936A1 (de) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Krebstherapie mittels CLDN6-zielgerichteter Antikörper im lebenden Organismus
NZ605449A (en) 2010-07-09 2015-03-27 Genentech Inc Anti-neuropilin antibodies and methods of use
WO2012010582A1 (en) 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use
EP2597945B1 (de) 2010-07-26 2020-07-22 Trianni, Inc. Transgene tiere und verfahren zu ihrer verwendung
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
BR112013002535A2 (pt) 2010-08-03 2019-09-24 Hoffmann La Roche biomarcadores de leucemia linfocítica crônica (cll)
RU2013106217A (ru) 2010-08-05 2014-09-10 Ф. Хоффманн-Ля Рош Аг Гибридный белок из антитела против мнс и противовирусного цитокина
WO2012021648A1 (en) 2010-08-10 2012-02-16 Amgen Inc. Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies
MX2013001336A (es) 2010-08-13 2013-03-08 Roche Glycart Ag Anticuerpos ani-tenascina c a2 y metodos de utilizacion.
CN104474546A (zh) 2010-08-13 2015-04-01 弗·哈夫曼-拉罗切有限公司 用于疾病治疗的针对IL-1β和IL-18的抗体
AU2011288487B2 (en) 2010-08-13 2015-10-01 Roche Glycart Ag Anti-FAP antibodies and methods of use
CN103080134B (zh) 2010-08-20 2015-11-25 诺华股份有限公司 表皮生长因子受体3(her3)的抗体
DK2612151T3 (en) 2010-08-31 2017-10-02 Genentech Inc BIOMARKETS AND METHODS OF TREATMENT
WO2012028703A1 (en) 2010-09-02 2012-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for the prognosis of the progression of cancer
US8999335B2 (en) 2010-09-17 2015-04-07 Compugen Ltd. Compositions and methods for treatment of drug resistant multiple myeloma
US8993727B2 (en) 2010-09-22 2015-03-31 Amgen Inc. Carrier immunoglobulins and uses thereof
CA3182320A1 (en) 2010-09-23 2012-03-29 Precision Biologics, Inc. Colon and pancreas cancer peptidomimetics
KR20130130709A (ko) 2010-09-29 2013-12-02 어젠시스 인코포레이티드 191p4d12 단백질에 결합하는 항체 약물 컨쥬게이트(ａｄｃ)
JP2013543384A (ja) 2010-10-05 2013-12-05 ノバルティス アーゲー 抗−ｉｌ１２ｒベータ１抗体ならびに自己免疫性および炎症性疾患の処置おけるその使用
EA031044B1 (ru) 2010-10-13 2018-11-30 Янссен Байотек, Инк. Человеческие антитела к онкостатину м и способы их применения
JP6163429B2 (ja) 2010-11-10 2017-07-12 ジェネンテック， インコーポレイテッド 神経疾患免疫治療のための方法及び組成物
EP2643694B1 (de) 2010-11-24 2018-01-03 Litron Laboratories Ltd. Schneller in-vivo-genmutations-assay auf basis des pig-a-gens
EP2643353A1 (de) 2010-11-24 2013-10-02 Novartis AG Multispezifische moleküle
NZ609493A (en) 2010-12-16 2015-11-27 Genentech Inc Diagnosis and treatments relating to th2 inhibition
EA028744B1 (ru) 2010-12-20 2017-12-29 Дженентек, Инк. Антитела против мезотелина и иммуноконъюгаты
KR20130118925A (ko) 2010-12-22 2013-10-30 제넨테크, 인크. 항-pcsk9 항체 및 사용 방법
JP2014502607A (ja) 2011-01-03 2014-02-03 エフ．ホフマン−ラ ロシュ アーゲー 抗ｄｉｇ抗体およびペプチドと結合体化しているジゴキシゲニンの複合体の薬学的組成物
KR20140009311A (ko) 2011-01-18 2014-01-22 암젠 인크 Nav1.7 넉아웃 마우스 및 이의 용도
MX354359B (es) 2011-03-29 2018-02-28 Roche Glycart Ag Variantes de fragmento cristalizable (fc) de los anticuerpos.
RU2013143358A (ru) 2011-04-07 2015-05-20 Дженентек, Инк. Анти-fgfr4 антитела и способы их применения
WO2012136552A1 (en) 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
US9409987B2 (en) 2011-04-15 2016-08-09 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
CN103796678B (zh) 2011-04-20 2018-02-27 健玛保 针对her2的双特异性抗体
US20140170149A1 (en) 2011-04-20 2014-06-19 Genmab A/S Bispecific antibodies against her2 and cd3
MX2013013054A (es) 2011-05-12 2014-02-20 Genentech Inc Metodo de monitoreo de lc-ms/ms de reaccion multiple para detectar anticuerpos terapeuticos en muestras de animales utilizando peptidos de firma de estructura.
RS58087B1 (sr) 2011-05-13 2019-02-28 Ganymed Pharmaceuticals Gmbh Antitela za lečenje kancera koji eksprimira klaudin 6
PE20140995A1 (es) 2011-05-16 2014-08-23 Genentech Inc Agonistas de fgfr1 y sus metodos de uso
KR102046666B1 (ko) 2011-05-25 2019-11-19 이나뜨 파르마 염증성 장애의 치료를 위한 항-kir 항체
AR086543A1 (es) 2011-05-25 2014-01-08 Bg Medicine Inc Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
SG10201902706VA (en) 2011-06-03 2019-04-29 Xoma Technology Ltd Antibodies specific for tgf-beta
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
BR112013032235A2 (pt) 2011-06-15 2016-11-22 Hoffmann La Roche anticorpos do receptor de epo anti-humano e métodos de uso
JP6247209B2 (ja) 2011-06-28 2017-12-13 オックスフォード ビオトヘラペウトイクス エルティーディー． Ａｄｐリボシルシクラーゼ２に対する抗体
AU2012277376B2 (en) 2011-06-30 2016-11-24 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
AR086823A1 (es) 2011-06-30 2014-01-22 Genentech Inc Formulaciones de anticuerpo anti-c-met, metodos
PL2726099T3 (pl) 2011-07-01 2018-12-31 Novartis Ag Sposób leczenia zaburzeń metabolicznych
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
EP2731970B1 (de) 2011-07-15 2018-11-28 MorphoSys AG Antikörper mit kreuzreaktion auf makrophagenmigrations-inhibitorfaktor (mif) und d-dopachrom-tautomerase (d-dt)
US9175074B2 (en) 2011-08-04 2015-11-03 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
KR101968499B1 (ko) 2011-08-04 2019-04-12 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
HUE030137T2 (en) 2011-08-04 2017-04-28 Toray Industries Pharmaceutical preparation for the treatment and / or prevention of cancer
WO2013022091A1 (ja) 2011-08-11 2013-02-14 小野薬品工業株式会社 Ｐｄ－１アゴニストからなる自己免疫疾患治療剤
CA2842375A1 (en) 2011-08-17 2013-02-21 Erica Jackson Neuregulin antibodies and uses thereof
RU2014109985A (ru) 2011-08-17 2015-09-27 Дженентек, Инк. Ингибирование ангиогенеза в рефрактерных опухолях
BR112014003999A2 (pt) 2011-08-23 2017-06-13 Roche Glycart Ag anticorpo isolado que se liga a um epítopo próximo da membrana de mcsp humano, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de indivíduos portadores de câncer, método de undução da lise celular em indivíduos e teste imuno-histoquímico de mcsp
WO2013026839A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
KR101723273B1 (ko) 2011-08-23 2017-04-04 로슈 글리카트 아게 2 개의 ｆａｂ 단편을 포함하는 fc-부재 항체 및 이용 방법
MX2014003094A (es) 2011-09-15 2014-04-25 Genentech Inc Metodos para promover diferenciacion.
CN107056936B (zh) 2011-09-19 2021-09-03 科马布有限公司 免疫球蛋白基因多样性的操纵及多抗体治疗剂
CN103930111A (zh) 2011-09-19 2014-07-16 霍夫曼-拉罗奇有限公司 包含c-met拮抗剂和b-raf拮抗剂的组合治疗
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9663573B2 (en) 2011-10-05 2017-05-30 Genentech, Inc. Methods of treating liver conditions using Notch2 antagonists
CN104080471B (zh) 2011-10-14 2018-08-10 诺华股份有限公司 用于Wnt途径相关疾病的抗体和方法
US9738727B2 (en) 2011-10-14 2017-08-22 Genentech, Inc. Anti-HtrA1 antibodies and methods of use
WO2013056148A2 (en) 2011-10-15 2013-04-18 Genentech, Inc. Methods of using scd1 antagonists
WO2013059531A1 (en) 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
SG11201401815XA (en) 2011-10-28 2014-05-29 Genentech Inc Therapeutic combinations and methods of treating melanoma
CN104039320B (zh) 2011-11-09 2019-10-15 百时美施贵宝公司 血液恶性肿瘤用抗-cxcr4抗体的治疗
RU2014124842A (ru) 2011-11-21 2015-12-27 Дженентек, Инк. Очистка анти-с-мет антител
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US20130251703A1 (en) 2011-12-05 2013-09-26 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3
SG11201402739YA (en) 2011-12-05 2014-06-27 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
EP2788024A1 (de) 2011-12-06 2014-10-15 F.Hoffmann-La Roche Ag Antikörper-formulierung
CN104144946A (zh) 2011-12-19 2014-11-12 爱克索马美国有限责任公司 治疗痤疮的方法
SG10201913164YA (en) 2011-12-20 2020-03-30 Regeneron Pharma Humanized light chain mice
EP2794656B1 (de) 2011-12-21 2019-02-27 Novartis AG Zusammensetzungen die gegen faktor p und c5 gerichtete antikörper enthalten
BR112014013035A2 (pt) 2011-12-22 2018-10-09 Hoffmann La Roche métodos de seleção de células, conjuntos de expressão bicistrônica, células eucarióticas, vetores lentivirais, uso de vetor lentiviral, bibliotecas de ventores lentivirais e de células eucarióticas, métodos de seleção de células, fluxos de trabalho e uso de célula
WO2013092743A2 (en) 2011-12-22 2013-06-27 F. Hoffmann-La Roche Ag Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
CA2853955C (en) 2011-12-22 2021-09-28 F. Hoffmann-La Roche Ag Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
AR089434A1 (es) 2011-12-23 2014-08-20 Genentech Inc Procedimiento para preparar formulaciones con alta concentracion de proteinas
JP6242813B2 (ja) 2012-01-18 2017-12-06 ジェネンテック， インコーポレイテッド 抗ｌｒｐ５抗体及び使用方法
WO2013109856A2 (en) 2012-01-18 2013-07-25 Genentech, Inc. Methods of using fgf19 modulators
IN2014KN00848A (de) 2012-02-01 2015-10-02 Compugen Ltd
CN113398268A (zh) 2012-02-11 2021-09-17 霍夫曼-拉罗奇有限公司 R-spondin易位及其使用方法
WO2013120929A1 (en) 2012-02-15 2013-08-22 F. Hoffmann-La Roche Ag Fc-receptor based affinity chromatography
AU2013223143B2 (en) 2012-02-21 2017-12-21 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
US9260513B2 (en) 2012-02-21 2016-02-16 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
DK2824114T3 (da) 2012-02-21 2019-07-29 Toray Industries Farmaceutisk sammensætning til behandling af cancer
KR102005786B1 (ko) 2012-02-21 2019-07-31 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
EP2816893A1 (de) 2012-02-22 2014-12-31 Amgen Inc. Aus induzierten pluripotenten stammzellen gewonnene autologe säugetiere und entsprechende verfahren
BR112014018964A2 (pt) 2012-03-13 2020-05-12 F. Hoffmann-La Roche Ag Anticorpo anti-vegf e uso de um anticorpo anti-vegf
NZ629697A (en) 2012-03-15 2017-01-27 Janssen Biotech Inc Human anti-cd27 antibodies, methods and uses
AU2013240261A1 (en) 2012-03-27 2014-09-18 Genentech, Inc. Diagnosis and treatments relating to HER3 inhibitors
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
BR112014024209A2 (pt) 2012-03-30 2018-04-10 Toray Industries composição farmacêutica, agente farmacêutico e método de tratamento e/ou prevenção de cancêr da vesicula biliar
DK2832365T3 (en) 2012-03-30 2018-01-08 Toray Industries PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR PREVENTION OF LIVING CANCER
US10114023B2 (en) 2012-04-18 2018-10-30 Massachusetts Institute Of Technology Method of enhancing the efficacy of anti-hepatocyte growth factor receptor breast cancer therapy by administering an inhibitor of menaINV
EA035344B1 (ru) 2012-04-20 2020-05-29 Мерюс Н.В. Способ получения двух антител из одной клетки-хозяина
US9212227B2 (en) 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
WO2013165940A1 (en) 2012-05-01 2013-11-07 Genentech, Inc. Anti-pmel17 antibodies and immunoconjugates
ES2729729T3 (es) 2012-05-07 2019-11-05 Astellas Pharma Inc Anticuerpos que se unen a PLAC1 y bloquean la interacción entre PLAC1 y FGF7
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
EP3725810B1 (de) 2012-05-23 2022-07-06 Astellas Pharma Inc. Kombinationstherapie mit antikörpern gegen claudin 18.2 zur behandlung von krebs
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
EP2852840B1 (de) 2012-05-23 2019-10-09 F.Hoffmann-La Roche Ag Auswahlverfahren für therapeutika
EP3254695B1 (de) 2012-05-23 2020-09-09 Astellas Pharma Inc. Kombinationstherapie mit antikörpern gegen claudin 18.2 zur behandlung von krebs
WO2013174403A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174003A1 (en) 2012-05-24 2013-11-28 Mountgate Group Limited Compositions and methods related to prevention and treatment of rabies infection
WO2013188855A1 (en) 2012-06-15 2013-12-19 Genentech, Inc. Anti-pcsk9 antibodies, formulations, dosing, and methods of use
JP6285923B2 (ja) 2012-06-22 2018-02-28 トラスティーズ・オブ・ダートマス・カレッジ 新規ＶＩＳＴＡ−Ｉｇコンストラクト及び自己免疫、アレルギー性及び炎症性障害の処置のためのＶＩＳＴＡ−Ｉｇの使用
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
SG11201407420RA (en) 2012-07-04 2015-02-27 Hoffmann La Roche Covalently linked antigen-antibody conjugates
RU2630296C2 (ru) 2012-07-04 2017-09-06 Ф. Хоффманн-Ля Рош Аг Антитела к биотину и способы их применения
RU2630664C2 (ru) 2012-07-04 2017-09-11 Ф. Хоффманн-Ля Рош Аг Антитела к теофиллину и способы их применения
CA3188124A1 (en) 2012-07-05 2014-01-09 Genentech, Inc. Expression and secretion system
EP3632462A1 (de) 2012-07-06 2020-04-08 Genmab B.V. Dimerprotein mit dreifacher mutation
AU2013285355A1 (en) 2012-07-06 2015-01-29 Genmab B.V. Dimeric protein with triple mutations
EA201590172A1 (ru) 2012-07-09 2015-09-30 Дженентек, Инк. ИММУНОКОНЪЮГАТЫ, СОДЕРЖАЩИЕ АНТИТЕЛА К CD79b
IN2014DN10652A (de) 2012-07-09 2015-09-11 Genentech Inc
PE20150325A1 (es) 2012-07-09 2015-03-05 Genentech Inc Inmunoconjugados que comprenden anticuerpos anti-cd22 y derivados de nemorrubicina.
AU2013288929A1 (en) 2012-07-09 2014-12-04 Genentech, Inc. Immunoconjugates comprising anti-CD22 antibodies
WO2014009465A1 (en) 2012-07-13 2014-01-16 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
SG11201500903XA (en) 2012-08-07 2015-03-30 Genentech Inc Combination therapy for the treatment of glioblastoma
KR102355959B1 (ko) 2012-08-23 2022-01-27 어젠시스 인코포레이티드 158p1d7 단백질에 결합하는 항체 약물 컨쥬게이트(ａｄｃ)
AU2013312211B2 (en) 2012-09-07 2018-03-29 King's College London VISTA modulators for diagnosis and treatment of cancer
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
EP2904016B1 (de) 2012-10-08 2018-11-14 Roche Glycart AG Fc-freie antikörper mit zwei fab-fragmenten sowie verwendungsverfahren dafür
EP2914621B1 (de) 2012-11-05 2023-06-07 Foundation Medicine, Inc. Neuartige ntrk1-fusionsmoleküle und verwendungen davon
AU2013342163B2 (en) 2012-11-08 2018-08-16 F. Hoffmann-La Roche Ltd IL-6 antagonists and uses thereof
AR093378A1 (es) 2012-11-08 2015-06-03 Hoffmann La Roche PROTEINAS LIGANTES DE ANTIGENO HER3 DE UNION A LA HORQUILLA b DE HER3
EA201892509A1 (ru) 2012-11-13 2019-04-30 Дженентек, Инк. Антитела к гемагглютинину и способы применения
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
SI2925350T1 (sl) 2012-12-03 2019-04-30 Bristol-Myers Squibb Company Izboljšanje protirakave aktivnosti imunomodulatornih FC fuzijskih proteinov
PL2928921T3 (pl) 2012-12-05 2021-06-28 Novartis Ag Kompozycje i sposoby dla przeciwciał celujących w epo
WO2014099997A1 (en) 2012-12-18 2014-06-26 Novartis Ag Compositions and methods that utilize a peptide tag that binds to hyaluronan
WO2014106176A1 (en) 2012-12-28 2014-07-03 Precision Biologics, Inc. Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
WO2014107739A1 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Antibodies against pcsk9
KR20220156667A (ko) 2013-01-10 2022-11-25 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
CA2898326C (en) 2013-01-18 2022-05-17 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
MX371052B (es) 2013-02-08 2020-01-14 Novartis Ag Anticuerpos anti-il-17a y su uso en el tratamiento de trastornos autoinmunes e inflamatorios.
HRP20221319T1 (hr) 2013-02-20 2022-12-23 Astellas Pharma Inc. Kombinirana terapija koja uključuje antitijela protiv klaudina 18.2 za liječenje raka
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
CA2900097A1 (en) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Methods of treating cancer and preventing drug resistance
US20140242083A1 (en) 2013-02-26 2014-08-28 Roche Glycart Ag Anti-mcsp antibodies
EP2964260A2 (de) 2013-03-06 2016-01-13 F. Hoffmann-La Roche AG Verfahren zur behandlung und prävention einer antikrebsmittelresistenz
EP3611189A1 (de) 2013-03-14 2020-02-19 Novartis AG Antikörper gegen notch 3
CN105307683A (zh) 2013-03-14 2016-02-03 基因泰克公司 治疗癌症和预防癌症药物抗性的方法
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
BR112015022576A2 (pt) 2013-03-14 2017-10-24 Genentech Inc produto farmacêutico e seu uso, kit e método para tratar uma disfunção hiperproliferativa
JP6436965B2 (ja) 2013-03-14 2018-12-12 ジェネンテック， インコーポレイテッド 抗ｂ７−ｈ４抗体及びイムノコンジュゲート
US9598485B2 (en) 2013-03-15 2017-03-21 Ac Immune S.A. Anti-tau antibodies and methods of use
BR112015023203A8 (pt) 2013-03-15 2018-01-23 Constellation Pharmaceuticals Inc métodos para tratamento de câncer, método para aumentar a eficiência de um tratamento de câncer, método para retardar e/ou prevenir o desenvolvimento de câncer, método para tratar um indivíduo com câncer, método para aumentar a sensibilidade para um agente de terapia para câncer, método para estender um período de sensibilidade e método para estender a duração da resposta para uma terapia para câncer.
JP6466904B2 (ja) 2013-03-15 2019-02-06 ヤンセン バイオテツク，インコーポレーテツド インターフェロンアルファ及びオメガ抗体アンタゴニスト
BR112015023120A2 (pt) 2013-03-15 2017-11-21 Genentech Inc método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado
KR20150128707A (ko) 2013-03-15 2015-11-18 제넨테크, 인크. 간암의 진단 및 치료를 위한 조성물 및 방법
CN105143265A (zh) 2013-03-15 2015-12-09 豪夫迈·罗氏有限公司 抗CRTh2抗体及其用途
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
SI2976360T1 (sl) 2013-03-18 2020-04-30 Astellas Pharma Inc. Terapija, ki vključuje protitelesa proti Klavdinu 18.2 za zdravljenje raka
AU2014261630B2 (en) 2013-04-29 2019-05-09 F. Hoffmann-La Roche Ag Human FcRn-binding modified antibodies and methods of use
CN105164158A (zh) 2013-04-29 2015-12-16 豪夫迈·罗氏有限公司 消除对FcRn-结合的抗-IGF-1R抗体及其在血管性眼病治疗中的用途
RU2019108429A (ru) 2013-04-29 2019-05-06 Ф. Хоффманн-Ля Рош Аг Модифицированные асимметричные антитела, связывающие fc-рецептор, и способы их применения
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
JP6612214B2 (ja) 2013-05-20 2019-11-27 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体抗体及び使用方法
CA2922704A1 (en) 2013-05-24 2014-11-27 Neil R. Cashman Cell senescence markers as diagnostic and therapeutic targets
AR096601A1 (es) 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
EP2820947A1 (de) 2013-07-05 2015-01-07 B Cell Design Transgenes nichtmenschliches Säugetier zur Herstellung chimärer humaner Immunglobulin-E-Antikörper
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
EP3027208B1 (de) 2013-07-31 2020-06-24 Biontech AG Diagnose und therapie von krebs mit krebsstammzellen
RU2679657C2 (ru) 2013-08-01 2019-02-12 Эдженсис, Инк. Конъюгаты антител с лекарственными средствами, связывающиеся с белками cd37
MX2016001969A (es) 2013-08-14 2016-06-02 Novartis Ag Metodos para tratar la miositis por cuerpos de inclusion esporadica.
CA2922439A1 (en) 2013-08-29 2015-03-05 University Of Copenhagen Anti-adam12 antibodies for the treatment of cancer
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
MX2016003248A (es) 2013-09-17 2016-06-07 Genentech Inc Metodos de uso de anticuerpos anti-lgr5.
AU2014323523B2 (en) 2013-09-20 2020-02-20 Bristol-Myers Squibb Company Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
EP3051942B1 (de) 2013-10-01 2020-09-02 Kymab Limited Tiermodelle und therapeutische moleküle
BR112016007635A2 (pt) 2013-10-11 2017-09-12 Genentech Inc inibidores de nsp4 e métodos de uso
CA2925598A1 (en) 2013-10-18 2015-04-23 Genentech, Inc. Anti-rspo antibodies and methods of use
MX2016005159A (es) 2013-10-23 2016-07-05 Genentech Inc Metodos de diagnostico y tratamiento de trastornos eosinofilicos.
KR102331054B1 (ko) 2013-11-06 2021-11-24 얀센 바이오테크 인코포레이티드 항-ccl17 항체
SI3071597T1 (sl) 2013-11-21 2020-11-30 F. Hoffmann-La Roche Ag Anti alfa-sinukleinska protitelesa in postopki uporabe
CA2931340A1 (en) 2013-12-13 2015-06-18 Genentech, Inc. Anti-cd33 antibodies and immunoconjugates
AU2014364601A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Methods of treating HER2-positive cancers using PD-1 axis binding antagonists and anti-HER2 antibodies
US20150210772A1 (en) 2013-12-17 2015-07-30 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
US20150190506A1 (en) 2013-12-17 2015-07-09 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
PE20210107A1 (es) 2013-12-17 2021-01-19 Genentech Inc Anticuerpos anti-cd3 y metodos de uso
TWI728373B (zh) 2013-12-23 2021-05-21 美商建南德克公司 抗體及使用方法
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
EP3087098B1 (de) 2013-12-24 2020-04-08 Janssen Pharmaceutica NV Anti-vista-antikörper und -fragmente
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
KR102278429B1 (ko) 2014-01-03 2021-07-16 에프. 호프만-라 로슈 아게 공유 연결된 폴리펩티드 독소-항체 콘쥬게이트
CN105873615B (zh) 2014-01-03 2020-12-25 豪夫迈·罗氏有限公司 共价连接的helicar-抗helicar抗体缀合物及其用途
KR20160104628A (ko) 2014-01-03 2016-09-05 에프. 호프만-라 로슈 아게 이중특이성 항-합텐/항-혈액뇌장벽 수용체 항체, 그의 복합체 및 혈액뇌장벽 셔틀로서 그의 용도
KR20160107190A (ko) 2014-01-15 2016-09-13 에프. 호프만-라 로슈 아게 변형된 FcRn-결합 및 유지된 단백질 A-결합 성질을 갖는 Fc-영역 변이체
KR20160111469A (ko) 2014-01-24 2016-09-26 제넨테크, 인크. 항-steap1 항체 및 면역접합체를 사용하는 방법
ES2873248T3 (es) 2014-02-08 2021-11-03 Hoffmann La Roche Métodos para tratar la enfermedad de Alzheimer
TWI705824B (zh) 2014-02-08 2020-10-01 美商建南德克公司 治療阿茲海默症之方法
SG10201808259TA (en) 2014-02-12 2018-10-30 Genentech Inc Anti-jagged1 antibodies and methods of use
EP3107574A2 (de) 2014-02-21 2016-12-28 F. Hoffmann-La Roche AG Anti-il-13/il-17 bispezifische antikörper und verwendungen davon
EP2910645A1 (de) 2014-02-25 2015-08-26 STRATIFYER Molecular Pathology GmbH Verfahren und Zusammensetzungen zur Vorhersage der therapeutischen Wirksamkeit von Krebsbehandlungen und Krebsprognose bei Antikörperbehandlung
CN106103730B (zh) 2014-03-14 2021-06-08 豪夫迈·罗氏有限公司 用于分泌异源多肽的方法和组合物
WO2015140591A1 (en) 2014-03-21 2015-09-24 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
JP2017516458A (ja) 2014-03-24 2017-06-22 ジェネンテック， インコーポレイテッド ｃ−ｍｅｔ拮抗剤による癌治療及びｃ−ｍｅｔ拮抗剤のＨＧＦ発現との相関
EP3126386A1 (de) 2014-03-31 2017-02-08 F. Hoffmann-La Roche AG Kombinationstherapie mit antiangiogenesewirkstoffen und ox40-bindenden agonisten
KR20160145624A (ko) 2014-03-31 2016-12-20 제넨테크, 인크. 항-ox40 항체 및 사용 방법
CN113092788A (zh) 2014-04-02 2021-07-09 豪夫迈·罗氏有限公司 检测多特异性抗体轻链错配的方法
JP6649895B2 (ja) 2014-04-18 2020-02-19 アクセルロン ファーマ， インコーポレイテッド 赤血球レベルを増加させ、そして鎌状赤血球症を処置するための方法
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
WO2015164615A1 (en) 2014-04-24 2015-10-29 University Of Oslo Anti-gluten antibodies and uses thereof
RU2016150370A (ru) 2014-05-22 2018-06-26 Дженентек, Инк. Антитела и иммуноконъюгаты против GPC3
WO2015179835A2 (en) 2014-05-23 2015-11-26 Genentech, Inc. Mit biomarkers and methods using the same
PE20170441A1 (es) 2014-06-06 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos
CN106604743A (zh) 2014-06-09 2017-04-26 奥特吉尼克斯制药公司 用于最佳骨形成的血清磷酸盐的有效和高效控制
EP3155015A1 (de) 2014-06-11 2017-04-19 F. Hoffmann-La Roche AG Anti-lgr5-antikörper und verwendungen davon
CN107073109B (zh) 2014-06-11 2021-08-06 凯西·A·格林 Vista激动剂和拮抗剂抑制或增强体液免疫的用途
TN2016000553A1 (en) 2014-06-13 2018-04-04 Acceleron Pharma Inc Methods and compositions for treating ulcers
US20230190750A1 (en) 2014-06-13 2023-06-22 Genentech, Inc. Methods of treating and preventing cancer drug resistance
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
US20170291939A1 (en) 2014-06-25 2017-10-12 Novartis Ag Antibodies specific for il-17a fused to hyaluronan binding peptide tags
EP3160991A2 (de) 2014-06-25 2017-05-03 Novartis AG Zusammensetzungen und verfahren für proteine mit langer wirkung
US20170290876A1 (en) 2014-06-25 2017-10-12 Novartis Ag Compositions and methods for long acting proteins
CN106659772B (zh) 2014-06-26 2021-08-31 耶鲁大学 在疾病和紊乱的治疗中调节肾酶的组合物和方法
TW201623329A (zh) 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
EP3166688A4 (de) 2014-07-08 2017-12-20 New York University Tau-bildgebungsliganden und deren verwendung in der diagnose und behandlung von tauopathie
CN107074925B (zh) 2014-07-10 2021-08-24 阿费里斯股份公司 用于预防和/或治疗亨廷顿氏病的物质和方法
RU2017103289A (ru) 2014-07-11 2018-08-14 Дженентек, Инк. Ингибирование пути notch
WO2016011052A1 (en) 2014-07-14 2016-01-21 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
JP6692343B2 (ja) 2014-08-01 2020-05-13 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 薬物としての使用のための抗ｃｄ４５ｒｃ抗体
CU24453B1 (es) 2014-08-07 2019-11-04 Novartis Ag Anticuerpos anti proteína similar a angiopoyetina 4
EP3194437B1 (de) 2014-08-07 2021-01-20 Novartis AG Antikörper gegen angiopoietinähnliches protein 4 und deren verwendung
HRP20220738T1 (hr) 2014-08-11 2022-08-19 Acerta Pharma B.V. Terapijske kombinacije inhibitora btk, inhibitora pd-1 i/ili inhibitora pd-l1
AU2015314744A1 (en) 2014-09-12 2017-03-02 Genentech, Inc. Anti-CLL-1 antibodies and immunoconjugates
CN113698488A (zh) 2014-09-12 2021-11-26 基因泰克公司 抗-b7-h4抗体及免疫缀合物
MA40576B1 (fr) 2014-09-12 2020-11-30 Genentech Inc Anticorps et immunoconjugués anti-her2
EP3197500A1 (de) 2014-09-17 2017-08-02 Genentech, Inc. Immunkonjugate mit anti-her2-antikörpern und pyrrolobenzodiazepinen
PL3262071T3 (pl) 2014-09-23 2020-08-10 F. Hoffmann-La Roche Ag Sposób stosowania immunokoniugatów anty-CD79b
EP3201226A2 (de) 2014-10-03 2017-08-09 Massachusetts Institute of Technology Antikörper zur bindung von ebola-glycoprotein und verwendungen davon
EP3207146B1 (de) 2014-10-15 2021-09-29 Amgen Inc. Promotor und regulatorische elemente zur verbesserten expression von heterologen genen in wirtszellen
US9732148B2 (en) 2014-10-16 2017-08-15 Genentech, Inc. Anti-α-synuclein antibodies and methods of use
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
WO2016070001A1 (en) 2014-10-31 2016-05-06 Jounce Therapeutics, Inc. Methods of treating conditions with antibodies that bind b7-h4
CA2966523A1 (en) 2014-11-03 2016-05-12 Genentech, Inc. Assays for detecting t cell immune subsets and methods of use thereof
US20160160290A1 (en) 2014-11-03 2016-06-09 Genentech, Inc. Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
US10738078B2 (en) 2014-11-03 2020-08-11 Bristol-Myers Squibb Company Use of caprylic acid precipitation for protein purification
EP3215528B1 (de) 2014-11-06 2019-08-07 F.Hoffmann-La Roche Ag Fc-region-varianten mit modifizierte fcrn-bindung und verfahren zur verwendung
CN107074966A (zh) 2014-11-06 2017-08-18 豪夫迈·罗氏有限公司 具有改变的FCRN‑和蛋白A‑结合性质的Fc区变体
SG11201703376QA (en) 2014-11-06 2017-05-30 Genentech Inc Combination therapy comprising ox40 binding agonists and tigit inhibitors
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention
EP3632931A1 (de) 2014-11-07 2020-04-08 Sesen Bio, Inc. Verbesserte il-6-antikörper
CN107105632A (zh) 2014-11-10 2017-08-29 豪夫迈·罗氏有限公司 肾病动物模型及其治疗剂
CN107172879B (zh) 2014-11-10 2021-11-05 豪夫迈·罗氏有限公司 抗白细胞介素-33抗体及其用途
EP3218397B8 (de) 2014-11-14 2021-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralisierende antikörper gegen ebola virus glykoprotein und deren verwendung
CN106999583A (zh) 2014-11-17 2017-08-01 豪夫迈·罗氏有限公司 包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
WO2016079219A1 (en) 2014-11-19 2016-05-26 Koninklijke Philips N.V. Diagnostic method employing hnl
EP3221361B1 (de) 2014-11-19 2021-04-21 Genentech, Inc. Multispezifische anti-transferrin-rezeptor- / anti-bace1-antikörper und verfahren zur verwendung
EP3845565A3 (de) 2014-11-19 2021-09-08 Genentech, Inc. Antikörper gegen bace1 und verwendung davon zur immuntherapie bei neuronalen erkrankungen
JP6779876B2 (ja) 2014-11-19 2020-11-04 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体抗体及びその使用方法
SI3789402T1 (sl) 2014-11-20 2022-10-28 F. Hoffmann-La Roche Ag Kombinirano zdravljenje z bispecifičnimi molekulami, ki vežejo antigen in aktivirajo celice T, ter antagonisti za vezavo osi PD-1
CN113773388A (zh) 2014-11-21 2021-12-10 百时美施贵宝公司 抗cd73抗体及其用途
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
LT3227336T (lt) 2014-12-05 2019-09-25 F. Hoffmann-La Roche Ag Anti-cd79b antikūnai ir jų naudojimo būdai
EP3226900A4 (de) 2014-12-05 2018-09-19 Immunext, Inc. Identifizierung von vsig8 als vermeintlicher vista-rezeptor und dessen verwendung zur herstellung von vista/vsig8-modulatoren
KR20170085595A (ko) 2014-12-10 2017-07-24 제넨테크, 인크. 혈뇌 장벽 수용체 항체 및 사용 방법
CN113563468A (zh) 2014-12-19 2021-10-29 雷根尼桑斯公司 结合人c6的抗体及其用途
AU2015365167B2 (en) 2014-12-19 2021-07-29 Chugai Seiyaku Kabushiki Kaisha Anti-C5 antibodies and methods of use
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
KR102644115B1 (ko) 2014-12-23 2024-03-05 브리스톨-마이어스 스큅 컴퍼니 Tigit에 대한 항체
WO2016111947A2 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
JP2018511557A (ja) 2015-01-22 2018-04-26 中外製薬株式会社 ２種以上の抗ｃ５抗体の組み合わせおよび使用方法
CN114773469A (zh) 2015-02-05 2022-07-22 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
WO2016128912A1 (en) 2015-02-12 2016-08-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor
US10711067B2 (en) 2015-03-03 2020-07-14 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
MX2017011380A (es) 2015-03-09 2018-04-26 Agensys Inc Conjugados anticuerpo-farmaco (adc) que se ligan a proteinas flt3.
WO2016149088A1 (en) 2015-03-13 2016-09-22 Bristol-Myers Squibb Company Use of alkaline washes during chromatography to remove impurities
AU2016233398A1 (en) 2015-03-16 2017-09-07 F. Hoffmann-La Roche Ag Methods of detecting and quantifying IL-13 and uses in diagnosing and treating Th2-associated diseases
WO2016146134A1 (en) 2015-03-16 2016-09-22 Aarhus Universitet Antibodies towards an extracellular region of nbcn1
WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
US20180105554A1 (en) 2015-03-20 2018-04-19 Bristol-Myers Squibb Company Use of dextran sulfate to enhance protein a affinity chromatography
WO2016153983A1 (en) 2015-03-20 2016-09-29 Bristol-Myers Squibb Company Use of dextran for protein purification
BR112017020091A2 (pt) 2015-03-20 2018-11-06 Aarhus Universitet inibidores de pcsk9 para tratamento de distúrbios do metabolismo de lipoproteínas
LT3271389T (lt) 2015-03-20 2020-05-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizuojantys antikūnai prieš gp120 ir jų panaudojimas
PL3273992T3 (pl) 2015-03-23 2020-11-16 Jounce Therapeutics, Inc. Przeciwciała przeciwko icos
CA2981312C (en) 2015-03-30 2023-09-26 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
US10167334B2 (en) 2015-04-03 2019-01-01 Xoma Technology Ltd. Treatment of cancer using anti-TGF-BETA and PD-1 antibodies
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
CN114736307A (zh) 2015-04-06 2022-07-12 阿塞勒隆制药公司 TGF-β超家族I型和II型受体异多聚体及其用途
CN107709364A (zh) 2015-04-07 2018-02-16 豪夫迈·罗氏有限公司 具有激动剂活性的抗原结合复合体及使用方法
ES2899227T3 (es) 2015-04-07 2022-03-10 Alector Llc Anticuerpos anti sortilina y métodos de uso de los mismos
WO2016165765A1 (en) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis
WO2016165762A1 (en) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
JP7044553B2 (ja) 2015-04-24 2022-03-30 ジェネンテック， インコーポレイテッド 結合ポリペプチドを含む細菌を特定する方法
JP2018520642A (ja) 2015-05-01 2018-08-02 ジェネンテック， インコーポレイテッド マスク抗ｃｄ３抗体及びその使用方法
WO2016179194A1 (en) 2015-05-04 2016-11-10 Jounce Therapeutics, Inc. Lilra3 and method of using the same
CN116196414A (zh) 2015-05-11 2023-06-02 豪夫迈·罗氏有限公司 治疗狼疮性肾炎的组合物和方法
IL295002A (en) 2015-05-12 2022-09-01 Genentech Inc Therapeutic and diagnostic methods for cancer containing a pd–l1 binding antagonist
WO2016196343A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Humanized anti-ebola virus glycoprotein antibodies and methods of use
KR20180012753A (ko) 2015-05-29 2018-02-06 제넨테크, 인크. 암에 대한 치료 및 진단 방법
HUE061253T2 (hu) 2015-05-29 2023-06-28 Bristol Myers Squibb Co Antitestek OX40 ellen és azok felhasználásai
LT3303394T (lt) * 2015-05-29 2020-10-12 Agenus Inc. Anti-ctla-4 antikūnai ir jų naudojimo būdai
JP2018516933A (ja) 2015-06-02 2018-06-28 ジェネンテック， インコーポレイテッド 抗ｉｌ−３４抗体を使用して神経学的疾患を治療するための組成物及び方法
WO2016196975A1 (en) 2015-06-03 2016-12-08 The United States Of America, As Represented By The Secretary Department Of Health & Human Services Neutralizing antibodies to hiv-1 env and their use
SG10201911349YA (en) 2015-06-05 2020-01-30 Genentech Inc Anti-tau antibodies and methods of use
BR112017021484A2 (pt) 2015-06-05 2018-07-03 Novartis Ag anticorpos de direcionamento à proteína morfogenética óssea 9 (bmp9) e métodos para os mesmos
KR20180025888A (ko) 2015-06-08 2018-03-09 제넨테크, 인크. 항-ox40 항체 및 pd-1 축 결합 길항제를 사용하여 암을 치료하는 방법
AU2016274585A1 (en) 2015-06-08 2017-12-14 Genentech, Inc. Methods of treating cancer using anti-OX40 antibodies
CA2988982A1 (en) 2015-06-12 2016-12-15 Alector Llc Anti-cd33 antibodies and methods of use thereof
US11174313B2 (en) 2015-06-12 2021-11-16 Alector Llc Anti-CD33 antibodies and methods of use thereof
US10017577B2 (en) 2015-06-15 2018-07-10 Genentech, Inc. Antibodies and immunoconjugates
PE20180330A1 (es) 2015-06-16 2018-02-13 Genentech Inc Anticuerpos madurados por afinidad y humanizados para fcrh5 y metodos para su uso
CN107847568B (zh) 2015-06-16 2022-12-20 豪夫迈·罗氏有限公司 抗cll-1抗体和使用方法
WO2016204966A1 (en) 2015-06-16 2016-12-22 Genentech, Inc. Anti-cd3 antibodies and methods of use
JP2018524312A (ja) 2015-06-17 2018-08-30 ジェネンテック， インコーポレイテッド 抗ｈｅｒ２抗体及び使用方法
KR20180018538A (ko) 2015-06-17 2018-02-21 제넨테크, 인크. Pd-1 축 결합 길항제 및 탁산을 사용하여 국소적 진행성 또는 전이성 유방암을 치료하는 방법
CN113999312A (zh) 2015-06-24 2022-02-01 豪夫迈·罗氏有限公司 具有定制亲和力的抗转铁蛋白受体抗体
WO2016207717A1 (en) 2015-06-24 2016-12-29 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
CN107922500A (zh) 2015-06-29 2018-04-17 洛克菲勒大学 具有增强的激动剂活性的抗cd40抗体
CN108473573A (zh) 2015-06-29 2018-08-31 豪夫迈·罗氏有限公司 Ii型抗cd20抗体用于器官移植中
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
CN108350072B (zh) 2015-08-03 2022-05-24 诺华股份有限公司 治疗fgf21相关病症的方法
EP4218792A1 (de) 2015-08-04 2023-08-02 Acceleron Pharma Inc. Zusammensetzung zur behandlung von myeloproliferativen erkrankungen
US10669343B2 (en) 2015-08-05 2020-06-02 Janssen Biotech, Inc. Anti-CD154 antibodies and methods of using them
WO2017024285A2 (en) 2015-08-06 2017-02-09 Xoma (Us) Llc Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
EP3334761B1 (de) 2015-08-13 2023-07-19 New York University Antikörperbasierte, für das {p}ser404-epitop von tau selektive moleküle und deren verwendungen in der diagnose und behandlung von tauopathie
TN2018000076A1 (en) 2015-09-09 2019-07-08 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
HUE053914T2 (hu) 2015-09-09 2021-07-28 Novartis Ag Csecsemõmirigy-stróma eredetû limfopoietinhez (TSLP-hez) kötõdõ ellenanyagok és az ellenanyagok alkalmazására szolgáló eljárások
EP3347054B1 (de) 2015-09-11 2021-05-05 Genmab A/S Dosierschemata für anti-tf-antikörper-arzneimittelkonjugate
MA44909A (fr) 2015-09-15 2018-07-25 Acerta Pharma Bv Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
CA2993423C (en) 2015-09-18 2024-03-12 Chugai Seiyaku Kabushiki Kaisha Il-8-binding antibodies and uses thereof
AU2016326666B2 (en) 2015-09-23 2023-06-15 Genentech, Inc. Optimized variants of anti-VEGF antibodies
CN108289954B (zh) 2015-09-24 2022-05-31 阿布维特罗有限责任公司 Hiv抗体组合物和使用方法
RU2638457C2 (ru) 2015-09-28 2017-12-13 Общество С Ограниченной Ответственностью "Онкомакс" Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
AU2016329057A1 (en) 2015-09-30 2018-04-12 Janssen Biotech, Inc. Antagonistic antibodies specifically binding human CD40 and methods of use
DK3356404T3 (da) 2015-10-02 2021-10-25 Hoffmann La Roche Anti-pd1-antistoffer og fremgangsmåder til anvendelse
AU2016333512B2 (en) 2015-10-02 2022-11-17 F. Hoffmann-La Roche Ag Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
TW201723190A (zh) 2015-10-22 2017-07-01 永斯醫療股份有限公司 用於測定icos表現之基因印記
EP3184547A1 (de) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg-antikörper und verfahren zur verwendung
KR102440160B1 (ko) 2015-10-30 2022-09-02 제넨테크, 인크. 항-HtrA1 항체 및 이의 사용 방법
TW201730211A (zh) 2015-10-30 2017-09-01 建南德克公司 抗因子d抗體及結合物
RS63125B1 (sr) 2015-11-03 2022-05-31 Janssen Biotech Inc Antitela koja se specifično vezuju za pd-1 i njihova upotreba
WO2017079768A1 (en) 2015-11-08 2017-05-11 Genentech, Inc. Methods of screening for multispecific antibodies
JP7048505B2 (ja) 2015-11-10 2022-04-05 パラクリン セラピューティクス エービー Ｐｄｇｆ－ｃｃ阻害剤および抗エストロゲン剤によるｅｒ陰性乳癌の処置
KR20180082563A (ko) 2015-11-19 2018-07-18 브리스톨-마이어스 스큅 컴퍼니 글루코코르티코이드-유도된 종양 괴사 인자 수용체 (gitr)에 대한 항체 및 그의 용도
AU2016359695A1 (en) 2015-11-23 2018-06-14 Acceleron Pharma Inc. Methods for treating eye disorders
WO2017095823A1 (en) 2015-11-30 2017-06-08 The Regents Of The University Of California Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
EP3383903A1 (de) 2015-11-30 2018-10-10 Bristol-Myers Squibb Company Humane ip-10-antikörper und deren verwendung
WO2017095939A1 (en) 2015-12-03 2017-06-08 Trianni, Inc. Enhanced immunoglobulin diversity
EP3178848A1 (de) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antikörper zur verringerung der bildung von antikörpern gegen medikamente
AU2016368469B2 (en) 2015-12-09 2023-11-02 F. Hoffmann-La Roche Ag Type II anti-CD20 antibody for reducing formation of anti-drug antibodies
KR20180087430A (ko) 2015-12-17 2018-08-01 얀센 바이오테크 인코포레이티드 Hla-dr에 특이적으로 결합하는 항체 및 이의 용도
KR102467124B1 (ko) 2015-12-18 2022-11-15 추가이 세이야쿠 가부시키가이샤 항-c5 항체 및 사용 방법
WO2017103895A1 (en) 2015-12-18 2017-06-22 Novartis Ag Antibodies targeting cd32b and methods of use thereof
EP3862365A1 (de) 2016-01-08 2021-08-11 F. Hoffmann-La Roche AG Verfahren zur behandlung von cea-positiven karzinomen unter verwendung von antagonisten mit pd-1-achsen-bindung und bispezifischen anti-cea-/anti-cd3-antikörpern
EP3402503B1 (de) 2016-01-13 2020-10-21 Acerta Pharma B.V. Therapeutische kombinationen aus einem antifolat und einem btk-hemmer
CN108602883A (zh) 2016-01-20 2018-09-28 基因泰克公司 用于阿尔茨海默氏病的高剂量治疗
WO2017125897A1 (en) 2016-01-21 2017-07-27 Novartis Ag Multispecific molecules targeting cll-1
IL260743B2 (en) 2016-02-04 2024-03-01 Trianni Inc Advanced production of antibodies
MX2018009800A (es) 2016-02-12 2018-11-09 Janssen Pharmaceutica Nv Anticuerpos y fragmentos anti-vista, usos de los mismos y procedimientos de identificacion de los mismos.
AU2017225854B2 (en) 2016-02-29 2020-11-19 Foundation Medicine, Inc. Therapeutic and diagnostic methods for cancer
IL307425A (en) 2016-03-04 2023-12-01 Univ Rockefeller CD40 antibodies with increased agonistic activity
AU2017228470A1 (en) 2016-03-04 2018-08-30 Bristol-Myers Squibb Company Combination therapy with anti-CD73 antibodies
US10443054B2 (en) 2016-03-06 2019-10-15 Massachusetts Institute Of Technology Methods for identifying and treating invasive/metastatic breast cancers
JP6430025B2 (ja) 2016-03-15 2018-11-28 中外製薬株式会社 Ｐｄ−１系結合アンタゴニストおよび抗ｇｐｃ３抗体を使用して癌を治療する方法
EP4273551A3 (de) 2016-03-25 2024-01-17 F. Hoffmann-La Roche AG Multiplex-gesamtantikörper- und antikörper-konjugierter arzneimittelquantifizierungstest
CA3018154A1 (en) 2016-03-28 2017-10-05 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancers
KR101796277B1 (ko) 2016-04-12 2017-11-13 앱클론(주) 안정성이 개선된 ｈｅｒ２에 특이적으로 결합하는 항체
EP3865511A1 (de) 2016-04-14 2021-08-18 F. Hoffmann-La Roche AG Anti-rspo3-antikörper und verfahren zur verwendung
MX2018012492A (es) 2016-04-15 2019-06-06 Genentech Inc Métodos para monitorear y tratar el cáncer.
EP3442579A4 (de) 2016-04-15 2019-12-18 Immunext Inc. Anti-human-vista-antikörper und verwendung davon
EA039322B1 (ru) * 2016-04-15 2022-01-13 Эйдженус Инк. Антитела против ctla-4 и способы их применения
AU2017248766A1 (en) 2016-04-15 2018-11-01 Genentech, Inc. Methods for monitoring and treating cancer
AU2017259869A1 (en) 2016-05-02 2018-09-27 F. Hoffmann-La Roche Ag The contorsbody - a single chain target binder
EA039084B1 (ru) 2016-05-09 2021-12-01 Бристол-Майерс Сквибб Компани Антитела к tl1a и их применения
JP7089483B2 (ja) 2016-05-11 2022-06-22 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 修飾された抗テネイシン抗体及び使用方法
ES2858151T3 (es) 2016-05-20 2021-09-29 Hoffmann La Roche Conjugados de PROTAC-anticuerpo y procedimientos de uso
EP3465221B1 (de) 2016-05-27 2020-07-22 H. Hoffnabb-La Roche Ag Bioanalytisches verfahren zur charakterisierung von ortsspezifischen antikörper-wirkstoff-konjugaten
EP3252078A1 (de) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Typ ii anti-cd20 antikörper und anti-cd20/cd3 bispecific antikörper zur behandlung von krebs
CN110603266A (zh) 2016-06-02 2019-12-20 豪夫迈·罗氏有限公司 用于治疗癌症的ii型抗cd20抗体和抗cd20/cd3双特异性抗体
AU2017276604B2 (en) 2016-06-06 2020-02-27 F. Hoffmann-La Roche Ag Fusion proteins for ophthalmology with increased eye retention
JP7043425B2 (ja) 2016-06-06 2022-03-29 ジェネンテック， インコーポレイテッド シルベストロール抗体－薬物コンジュゲート及び使用方法
JP7231411B2 (ja) 2016-06-15 2023-03-01 ノバルティス アーゲー 骨形成タンパク質６（ｂｍｐ６）の阻害剤を使用して疾患を処置する方法
EP3475298A1 (de) 2016-06-24 2019-05-01 H. Hoffnabb-La Roche Ag Multispezifische anti-polyubiquitin-antikörper
JP6983824B2 (ja) 2016-07-04 2021-12-17 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 新規抗体フォーマット
SI3484916T1 (sl) 2016-07-12 2021-08-31 H. Lundbeck A/S Protitelesa, specifična za hiperfosforiliran Tau, in postopki za uporabo le-teh
CN109757103B (zh) 2016-07-14 2024-01-02 百时美施贵宝公司 针对tim3的抗体及其用途
PT3496739T (pt) 2016-07-15 2021-06-21 Acceleron Pharma Inc Composições compreendendo polipéptidos actriia para uso no tratamento de hipertensão pulmonar
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
KR20190040972A (ko) 2016-07-27 2019-04-19 악셀레론 파마 인코포레이티드 골섬유증 치료 방법 및 조성물
MX2018015721A (es) 2016-07-29 2019-05-27 Chugai Pharmaceutical Co Ltd Anticuerpos biespecificos que exhiben actividad de funcion de cofactor fviii alternativa mejorada.
JP7148493B2 (ja) 2016-08-01 2022-10-05 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー 副甲状腺ホルモン受容体１（ｐｔｈ１ｒ）抗体およびその使用
EP3494141A4 (de) 2016-08-03 2020-04-08 Bio-Techne Corporation Identifizierung von vsig3/vista als ein neuartiger immuncheckpoint und verwendung davon zur immuntherapie
SG11201801024XA (en) 2016-08-05 2018-05-30 Chugai Pharmaceutical Co Ltd Therapeutic or preventive compositions for il-8-related diseases
JP2019530434A (ja) 2016-08-05 2019-10-24 ジェネンテック， インコーポレイテッド アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法
US11878060B2 (en) 2016-08-07 2024-01-23 Novartis Ag mRNA-mediated immunization methods
WO2018029124A1 (en) 2016-08-08 2018-02-15 F. Hoffmann-La Roche Ag Therapeutic and diagnostic methods for cancer
CN109689111B (zh) 2016-08-11 2024-04-05 基因泰克公司 吡咯并苯并二氮杂䓬前药及其抗体缀合物
EP3496530B1 (de) * 2016-08-11 2022-03-30 The Jackson Laboratory Verfahren und zusammensetzungen im zusammenhang mit der verbesserten überlebensfähigkeit von menschlichen roten blutzellen in genetisch modifizierten immundefizienten nichtmenschlichen tieren
CA3033661A1 (en) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
JP2019530646A (ja) 2016-08-12 2019-10-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ タンパク質精製法
JP7009448B2 (ja) 2016-08-12 2022-02-10 ヤンセン バイオテツク，インコーポレーテツド 強化されたアゴニスト活性を有する、Ｆｃが遺伝子操作を受けた抗ＴＮＦＲスーパーファミリーメンバー抗体及びその使用方法
WO2018044970A1 (en) 2016-08-31 2018-03-08 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
WO2018050878A1 (en) 2016-09-19 2018-03-22 F. Hoffmann-La Roche Ag Complement factor based affinity chromatography
EP3515455B1 (de) 2016-09-20 2021-04-14 Aarhus Universitet Verbindungen zur behandlung von störungen des lipoproteinstoffwechsels
UA124269C2 (uk) 2016-09-23 2021-08-18 Дженентек, Інк. Застосування антагоністу il-13 для лікування атопічного дерматиту
MX2019003543A (es) 2016-09-28 2019-06-17 Xoma Us Llc Anticuerpos que se fijan al interleucina-2 y sus usos.
EP3522933B1 (de) 2016-10-05 2021-12-15 F. Hoffmann-La Roche AG Verfahren zur herstellung von antikörperarzneimittelkonjugaten
AU2017340504A1 (en) 2016-10-05 2019-04-11 Acceleron Pharma, Inc. Compositions and method for treating kidney disease
KR20190072528A (ko) 2016-10-06 2019-06-25 제넨테크, 인크. 암에 대한 치료 및 진단 방법
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
EP3525815A2 (de) 2016-10-13 2019-08-21 Massachusetts Institute of Technology Antikörper zur bindung des zika-virus-hüllprotein und verwendungen davon
EP3532091A2 (de) 2016-10-29 2019-09-04 H. Hoffnabb-La Roche Ag Anti-mic-antikörper und verfahren zur verwendung
MD3535298T2 (ro) 2016-11-02 2022-01-31 Jounce Therapeutics Inc Anticorpi ai PD-1 și utilizări ale acestora
US11339209B2 (en) 2016-11-14 2022-05-24 Novartis Ag Compositions, methods, and therapeutic uses related to fusogenic protein minion
AR110074A1 (es) 2016-11-15 2019-02-20 H Lundbeck As Agentes, usos y métodos para el tratamiento de la sinucleinopatía
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
WO2018091720A1 (en) 2016-11-21 2018-05-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the prophylactic treatment of metastases
WO2018106781A1 (en) 2016-12-07 2018-06-14 Genentech, Inc Anti-tau antibodies and methods of use
WO2018106776A2 (en) 2016-12-07 2018-06-14 Genentech, Inc. Anti-tau antibodies and methods of use
IL307242A (en) 2016-12-07 2023-11-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
WO2018109058A1 (en) 2016-12-16 2018-06-21 H. Lundbeck A/S Agents, uses and methods
EP3559249A1 (de) 2016-12-21 2019-10-30 H. Hoffnabb-La Roche Ag Verfahren zum in-vitro-glycoengineering von antikörpern
AU2017381656B2 (en) 2016-12-21 2020-07-02 F. Hoffmann-La Roche Ag Re-use of enzymes in in vitro glycoengineering of antibodies
BR112019010485A2 (pt) 2016-12-21 2019-09-10 Hoffmann La Roche método para a produção de um anticorpo, anticorpo e formulação farmacêutica
CN106519034B (zh) 2016-12-22 2020-09-18 鲁南制药集团股份有限公司 抗pd-1抗体及其用途
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
EP3559029A2 (de) 2016-12-23 2019-10-30 Bristol-Myers Squibb Company Design von therapeutischem immunglobulin g4 für verbesserte bioanalytische und bioverarbeitungseigenschaften
CN110267985B (zh) 2017-01-04 2023-05-23 H.隆德贝克有限公司 用于治疗眼科疾病的特异性针对过度磷酸化τ蛋白的抗体
US20180244785A1 (en) 2017-01-09 2018-08-30 Merrimack Pharmaceuticals, Inc. Anti-fgfr antibodies and methods of use
AU2018218557B9 (en) 2017-02-08 2021-06-24 Novartis Ag FGF21 mimetic antibodies and uses thereof
EP3580235B1 (de) 2017-02-10 2024-05-01 The United States of America, as represented by the Secretary, Department of Health and Human Services Neutralisierende antikörper gegen das plasmodium-falciparum-circumsporozoit-protein und verwendung davon
JP6995127B2 (ja) 2017-02-10 2022-02-04 ジェネンテック， インコーポレイテッド 抗トリプターゼ抗体、その組成物、及びその使用
CA3051839A1 (en) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
EP3596122A1 (de) 2017-02-28 2020-01-22 Bristol-Myers Squibb Company Verwendung von anti-ctla-4-antikörpern mit verbessertem adcc zur erhöhung der immunreaktion auf einen impfstoff
CA3052670A1 (en) 2017-03-01 2018-09-07 Genentech, Inc. Diagnostic and therapeutic methods for cancer
JP7227151B2 (ja) 2017-03-22 2023-02-21 ジェネンテック， インコーポレイテッド 眼障害の治療のために最適化された抗体組成物
CA3054837A1 (en) 2017-03-24 2018-09-27 Novartis Ag Methods for preventing and treating heart disease
KR20230148855A (ko) 2017-03-30 2023-10-25 더 존스 홉킨스 유니버시티 생체거대분자의 정제를 위한 초분자 고친화성 단백질-결합 시스템
JP7247101B2 (ja) 2017-04-03 2023-03-28 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｓｔｅａｐ－１に結合する抗体
CN110382525B (zh) 2017-04-03 2023-10-20 豪夫迈·罗氏有限公司 免疫缀合物
CA3053357A1 (en) 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
PL3606954T3 (pl) 2017-04-05 2022-10-17 F. Hoffmann-La Roche Ag Przeciwciała anty-LAG3
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
PE20200150A1 (es) 2017-04-21 2020-01-17 Genentech Inc Uso de antagonistas de klk5 para el tratamiento de una enfermedad
JP2020517695A (ja) 2017-04-27 2020-06-18 テサロ， インコーポレイテッド リンパ球活性化遺伝子−３（ｌａｇ−３）に対する抗体薬およびそれらの使用
US11168129B2 (en) 2017-05-15 2021-11-09 University Of Rochester Broadly neutralizing anti-influenza human monoclonal antibody and uses thereof
BR112019021847A2 (pt) 2017-05-30 2020-06-02 Bristol-Myers Squibb Company Composições compreendendo um anticorpo anti-lag-3 ou um anticorpo anti-lag-3 e um anticorpo anti-pd-1 ou anti-pd-l1
BR112019020610A2 (pt) 2017-05-30 2020-04-22 Bristol-Myers Squibb Company tratamento de tumores positivos para o lag-3
BR112019025574A2 (pt) 2017-06-05 2020-06-23 Janssen Biotech, Inc. Anticorpos que se ligam especificamente ao pd-1 e métodos de uso
EP3634486A4 (de) 2017-06-05 2021-03-31 Janssen Biotech, Inc. Gentechnisch hergestellte multispezifische antikörper und andere multimere proteine mit asymmetrischen mutationen der ch2-ch3-region
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
CA3063659A1 (en) 2017-06-28 2019-01-03 Novartis Ag Methods for preventing and treating urinary incontinence
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
TWI823859B (zh) 2017-07-21 2023-12-01 美商建南德克公司 癌症之治療及診斷方法
WO2019020480A1 (en) 2017-07-24 2019-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) ANTIBODIES AND PEPTIDES FOR TREATING HCMV RELATED DISEASES
KR20200033798A (ko) 2017-08-03 2020-03-30 알렉터 엘엘씨 항-cd33 항체 및 이의 이용 방법
CN111263659A (zh) 2017-08-18 2020-06-09 约翰霍普金斯大学 用于蛋白纯化的超分子丝状组装体
WO2019048040A1 (en) 2017-09-06 2019-03-14 Ganymed Pharmaceuticals Gmbh ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER
MX2020002612A (es) 2017-09-07 2020-07-13 Univ Res Inst Inc Augusta Anticuerpos de la proteina de muerte celular programada 1.
EP3690050A4 (de) 2017-09-29 2021-06-16 Chugai Seiyaku Kabushiki Kaisha Multispezifisches antigenbindendes molekül mit blutgerinnungsfaktor viii (fviii)-cofaktorfunktionssubstituierender aktivität und pharmazeutische formulierung mit diesem molekül als wirkstoff
US20200317783A1 (en) 2017-10-06 2020-10-08 Ono Pharmaceutical Co., Ltd. Bispecific antibody
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
JP2021500930A (ja) 2017-11-01 2021-01-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｏｍｐボディ−多価標的結合物質
AU2018358904A1 (en) 2017-11-01 2020-04-16 F. Hoffmann-La Roche Ag TriFab-contorsbody
AU2018359967A1 (en) 2017-11-06 2020-04-23 Genentech, Inc. Diagnostic and therapeutic methods for cancer
CA3082365A1 (en) 2017-11-09 2019-05-16 Pinteon Therapeutics Inc. Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
EP3498293A1 (de) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Behandlung monogener erkrankungen mit einem anti-cd45rc-antikörper
CN111527107A (zh) 2017-12-21 2020-08-11 豪夫迈·罗氏有限公司 结合hla-a2/wt1的抗体
WO2019126472A1 (en) 2017-12-22 2019-06-27 Genentech, Inc. Use of pilra binding agents for treatment of a disease
JP7391868B2 (ja) 2017-12-22 2023-12-05 ジョウンセ セラピューティクス， インク． Ｌｉｌｒｂ２に対する抗体
KR20200104886A (ko) 2017-12-28 2020-09-04 난징 레전드 바이오테크 씨오., 엘티디. Pd-l1에 대한 항체 및 변이체
US11905327B2 (en) 2017-12-28 2024-02-20 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against TIGIT
US11440957B2 (en) 2017-12-29 2022-09-13 Alector Llc Anti-TMEM106B antibodies and methods of use thereof
US20220089720A1 (en) 2018-01-12 2022-03-24 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
SG11202004233UA (en) 2018-01-15 2020-06-29 Nanjing Legend Biotech Co Ltd Single-domain antibodies and variants thereof against pd-1
US20200339686A1 (en) 2018-01-16 2020-10-29 Lakepharma, Inc. Bispecific antibody that binds cd3 and another target
US20190225689A1 (en) 2018-01-22 2019-07-25 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-pd-1 antibodies
WO2019152715A1 (en) 2018-01-31 2019-08-08 Alector Llc Anti-ms4a4a antibodies and methods of use thereof
CN111868082A (zh) 2018-02-02 2020-10-30 博奥泰克尼公司 调节vista和vsig3的相互作用的化合物及其制备和使用方法
MA51793A (fr) 2018-02-08 2020-12-16 Hoffmann La Roche Molécules bispécifiques de liaison à l'antigène et procédés d'utilisation
TWI829667B (zh) 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合gprc5d之抗體
TWI804572B (zh) 2018-02-09 2023-06-11 日商小野藥品工業股份有限公司 雙特異性抗體
JP7418337B2 (ja) 2018-02-09 2024-01-19 ジェネンテック， インコーポレイテッド マスト細胞媒介性炎症性疾患の治療法及び診断法
TW202000702A (zh) 2018-02-26 2020-01-01 美商建南德克公司 用於抗ｔｉｇｉｔ拮抗劑抗體及抗ｐｄ－ｌ１拮抗劑抗體治療之投藥
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
CN112119090B (zh) 2018-03-15 2023-01-13 中外制药株式会社 对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
AU2019237926A1 (en) * 2018-03-21 2020-09-24 Crystal Bioscience Inc. Transgenic chicken that produces human antibodies
AU2019236865A1 (en) 2018-03-23 2020-10-01 Bristol-Myers Squibb Company Antibodies against MICA and/or MICB and uses thereof
CN111936625A (zh) 2018-03-29 2020-11-13 豪夫迈·罗氏有限公司 调节哺乳动物细胞中的生乳活性
WO2019191416A1 (en) 2018-03-29 2019-10-03 Bristol-Myers Squibb Company Methods of purifying monomeric monoclonal antibodies
SG11202006674QA (en) 2018-03-30 2020-08-28 Nanjing Legend Biotech Co Ltd Single-domain antibodies against lag-3 and uses thereof
JP7104458B2 (ja) 2018-04-02 2022-07-21 上海博威生物医薬有限公司 リンパ球活性化遺伝子－３（ｌａｇ－３）結合抗体およびその使用
TW202011029A (zh) 2018-04-04 2020-03-16 美商建南德克公司 偵測及定量fgf21之方法
AR115052A1 (es) 2018-04-18 2020-11-25 Hoffmann La Roche Anticuerpos multiespecíficos y utilización de los mismos
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
AU2019258468B2 (en) 2018-04-24 2023-06-29 Ampsource Biopharma Shanghai Inc. Antibody against TIM-3 and application thereof
US11958895B2 (en) 2018-05-03 2024-04-16 University Of Rochester Anti-influenza neuraminidase monoclonal antibodies and uses thereof
BR112020022642A2 (pt) 2018-05-07 2021-02-17 Genmab A/S método para tratar câncer em um indivíduo, e, estojo
IL278400B2 (en) 2018-05-07 2024-03-01 Genmab As Combination of an anti-PD-1 antibody and conjugation of a drug with an anti-TF antibody for use in the treatment of cancer
ES2955511T3 (es) 2018-05-14 2023-12-04 Werewolf Therapeutics Inc Polipéptidos de interleucina 2 activables y métodos de uso de los mismos
AU2019271149B2 (en) 2018-05-14 2023-07-13 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
JP2021524249A (ja) 2018-05-24 2021-09-13 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３抗体及びその使用
CR20200564A (es) 2018-05-24 2021-06-21 Janssen Biotech Inc Anticuerpos anti-tmeff2 monoespecificos y multiespecificos y sus usos
WO2019224718A2 (en) 2018-05-24 2019-11-28 Janssen Biotech, Inc. Psma binding agents and uses thereof
MX2020011828A (es) 2018-05-25 2021-02-09 Alector Llc Anticuerpos anti proteina alfa reguladora de se?ales (sirpa) y metodos de uso de los mismos.
TW202015726A (zh) 2018-05-30 2020-05-01 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
US20210277118A1 (en) 2018-06-21 2021-09-09 Daiichi Sankyo Company, Limited Compositions including cd3 antigen binding fragments and uses thereof
US20200030443A1 (en) 2018-06-23 2020-01-30 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
JP2021529520A (ja) 2018-06-29 2021-11-04 アレクトル エルエルシー 抗ｓｉｒｐ−ベータ１抗体及びその使用方法
ES2940311T3 (es) 2018-07-13 2023-05-05 Alector Llc Anticuerpos anti-sortilina y métodos de uso de los mismos
KR20210034622A (ko) 2018-07-18 2021-03-30 제넨테크, 인크. Pd-1 축 결합 길항제, 항 대사제, 및 백금 제제를 이용한 폐암 치료 방법
EA202190451A1 (ru) 2018-08-10 2021-07-13 Чугаи Сейяку Кабусики Кайся Анти-cd137 антигенсвязывающие молекулы и их применение
CN112638946A (zh) 2018-08-16 2021-04-09 坎塔吉亚有限责任公司 抗il1rap抗体组合物
TW202021618A (zh) 2018-08-17 2020-06-16 美商２３與我有限公司 抗ｉｌ１ｒａｐ抗體及其使用方法
US11548938B2 (en) 2018-08-21 2023-01-10 Quidel Corporation DbpA antibodies and uses thereof
MX2021002299A (es) 2018-08-31 2021-04-28 Alector Llc Anticuerpos de anti-cd33 y metodos para usarlos.
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
US20210371537A1 (en) 2018-09-18 2021-12-02 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof
JP2022501332A (ja) 2018-09-19 2022-01-06 ジェネンテック， インコーポレイテッド 膀胱がんの治療方法および診断方法
EP3626265A1 (de) 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human-cd45rc-antikörper und verwendungen davon
ES2955032T3 (es) 2018-09-21 2023-11-28 Hoffmann La Roche Métodos de diagnóstico para el cáncer de mama triple negativo
EP3854875A4 (de) 2018-09-21 2022-07-06 National University Corporation Tokyo Medical and Dental University Menschlicher monoklonaler antikörper, der spezifisch an humanes hmgb1 bindet, und pharmazeutische zusammensetzung zur behandlung oder vorbeugung von morbus alzheimer, die den menschlichen monoklonalen antikörper enthält
US20210290742A1 (en) * 2018-09-27 2021-09-23 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of using lysine deacetylase (kdac) inhibition to generate antigen specific memory t cell responses for durable immunotherapy
WO2020069398A1 (en) 2018-09-27 2020-04-02 Akrevia Therapeutics Inc. Masked cytokine polypeptides
TW202028244A (zh) 2018-10-09 2020-08-01 美商建南德克公司 用於確定突觸形成之方法及系統
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
WO2020081767A1 (en) 2018-10-18 2020-04-23 Genentech, Inc. Diagnostic and therapeutic methods for sarcomatoid kidney cancer
WO2020082209A1 (zh) 2018-10-22 2020-04-30 上海吉倍生物技术有限公司 抗cldn18.2抗体及其用途
CN113056287A (zh) 2018-10-24 2021-06-29 豪夫迈·罗氏有限公司 缀合的化学降解诱导剂及使用方法
TW202034958A (zh) 2018-10-30 2020-10-01 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
EP3877413A1 (de) 2018-11-06 2021-09-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und pharmazeutische zusammensetzungen zur behandlung von akuter myeloischer leukämie durch vernichtung von leukämischen stammzellen
JP2022509942A (ja) 2018-11-16 2022-01-25 ブリストル－マイヤーズ スクイブ カンパニー 抗ｎｋｇ２ａ抗体およびその使用
WO2020117257A1 (en) 2018-12-06 2020-06-11 Genentech, Inc. Combination therapy of diffuse large b-cell lymphoma comprising an anti-cd79b immunoconjugates, an alkylating agent and an anti-cd20 antibody
EP3894427A1 (de) 2018-12-10 2021-10-20 Genentech, Inc. Photovernetzende peptide zur stellenspezifischen konjugation an fc-haltige proteine
US20220064260A1 (en) 2018-12-14 2022-03-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8+cd45rclow tregs
GB201820547D0 (en) 2018-12-17 2019-01-30 Oxford Univ Innovation Modified antibodies
GB201820554D0 (en) 2018-12-17 2019-01-30 Univ Oxford Innovation Ltd BTLA antibodies
AR117327A1 (es) 2018-12-20 2021-07-28 23Andme Inc Anticuerpos anti-cd96 y métodos de uso de estos
EP3883609A2 (de) 2018-12-20 2021-09-29 The United States of America, as represented by the Secretary, Department of Health and Human Services Glykoprotein-spezifische monoklonale antikörper des ebola-virus und deren verwendungen
JP2022514290A (ja) 2018-12-20 2022-02-10 ジェネンテック， インコーポレイテッド 改変抗体ｆｃおよび使用方法
KR20210107721A (ko) 2018-12-21 2021-09-01 23앤드미 인코포레이티드 항-il-36 항체 및 이의 사용 방법
CN113166246A (zh) 2018-12-28 2021-07-23 四川科伦博泰生物医药股份有限公司 一种抗体及其用途
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
MX2021008434A (es) 2019-01-14 2021-09-23 Genentech Inc Metodos para tratar el cancer con un antagonista de union al eje de pd-1 y una vacuna de arn.
WO2020154293A1 (en) 2019-01-22 2020-07-30 Bristol-Myers Squibb Company Antibodies against il-7r alpha subunit and uses thereof
EP3914291A2 (de) 2019-01-22 2021-12-01 F. Hoffmann-La Roche AG Immunoglobulin-a-antikörper und verfahren zur herstellung und verwendung
CN113614107A (zh) 2019-01-23 2021-11-05 Encefa公司 Cd31竞争剂及其用途
EP3915581A4 (de) 2019-01-24 2023-03-22 Chugai Seiyaku Kabushiki Kaisha Neuartige krebsantigene und antikörper dieser antigene
JP2022518796A (ja) 2019-01-28 2022-03-16 メイプル バイオテック エルエルシー 肺、腎臓、または肝臓の線維症疾患の処置に使用するためのｐｓｍｐアンタゴニスト
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
JP7232925B2 (ja) 2019-02-15 2023-03-03 ウーシー バイオロジクス アイルランド リミテッド 改善された均一性を有する抗体薬物コンジュゲートの調製するプロセス
KR20210133234A (ko) 2019-02-18 2021-11-05 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 인간화 면역글로불린 유전자좌를 갖는 유전적으로 변형된 비-인간 동물
WO2020169472A2 (en) 2019-02-18 2020-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of inducing phenotypic changes in macrophages
MX2021010313A (es) 2019-02-27 2021-09-23 Genentech Inc Dosificacion para el tratamiento con anticuerpos anti-tigit y anti-cd20 o anti-cd38.
CA3131953A1 (en) 2019-03-01 2020-09-10 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof
AU2020231308A1 (en) 2019-03-01 2021-08-19 Allogene Therapeutics, Inc. DLL3 targeting chimeric antigen receptors and binding agents
AU2020238811A1 (en) 2019-03-08 2021-07-22 Genentech, Inc. Methods for detecting and quantifying membrane-associated proteins on extracellular vesicles
EP3947454A1 (de) 2019-03-27 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Rekombinante proteine mit cd40-aktivierenden eigenschaften
CN113646630A (zh) 2019-03-29 2021-11-12 百时美施贵宝公司 测量色谱树脂的疏水性的方法
TW202102544A (zh) 2019-04-04 2021-01-16 日商小野藥品工業股份有限公司 雙特異性抗體
US11136353B2 (en) 2019-04-15 2021-10-05 Qwixel Therapeutics Llc Fusion protein composition(s) comprising masked type I interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereof
US20220162338A1 (en) 2019-04-16 2022-05-26 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-fxi/fxia antibody and use thereof
AU2020258480A1 (en) 2019-04-19 2021-10-21 Genentech, Inc. Anti-mertk antibodies and their methods of use
AR118720A1 (es) 2019-04-19 2021-10-27 Janssen Biotech Inc Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3
AU2020261411A1 (en) 2019-04-26 2021-10-14 Allogene Therapeutics, Inc. Methods of manufacturing allogeneic car T cells
WO2020227228A2 (en) 2019-05-03 2020-11-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
WO2020226986A2 (en) 2019-05-03 2020-11-12 Genentech, Inc. Methods of treating cancer with an anti-pd-l1 antibody
JP2022532217A (ja) 2019-05-14 2022-07-13 ウェアウルフ セラピューティクス， インコーポレイテッド 分離部分及びその使用方法
AU2020275415A1 (en) 2019-05-14 2021-11-25 Genentech, Inc. Methods of using anti-CD79B immunoconjugates to treat follicular lymphoma
WO2020234399A1 (en) 2019-05-20 2020-11-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel anti-cd25 antibodies
US20230085439A1 (en) 2019-05-21 2023-03-16 University Of Georgia Research Foundation, Inc. Antibodies that bind human metapneumovirus fusion protein and their use
CA3140023A1 (en) 2019-06-11 2020-12-17 Alector Llc Anti-sortilin antibodies for use in therapy
CR20210607A (es) 2019-06-12 2022-01-21 Novartis Ag Anticuerpos de receptor de péptido natriurético 1 y métodos de uso
TW202115115A (zh) 2019-07-02 2021-04-16 瑞士商赫孚孟拉羅股份公司 免疫結合物
EP3998081A4 (de) 2019-07-05 2023-07-12 Ono Pharmaceutical Co., Ltd. Behandlung von hämatologischem krebs mit pd-1/cd3-protein mit doppelter spezifität
AR119393A1 (es) 2019-07-15 2021-12-15 Hoffmann La Roche Anticuerpos que se unen a nkg2d
CN114144436A (zh) 2019-07-24 2022-03-04 H.隆德贝克有限公司 抗mGluR5抗体及其用途
AU2020322222A1 (en) 2019-07-26 2022-03-24 Janssen Biotech, Inc. Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
WO2021020416A1 (ja) 2019-07-30 2021-02-04 小野薬品工業株式会社 二重特異性抗体
JP2022543551A (ja) 2019-07-31 2022-10-13 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｇｐｒｃ５ｄに結合する抗体
CR20220019A (es) 2019-07-31 2022-02-11 Hoffmann La Roche Anticuerpos que se fijan a gprc5d
CA3145885A1 (en) 2019-07-31 2021-02-04 Jeonghoon Sun Anti-ms4a4a antibodies and methods of use thereof
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
WO2021025140A1 (ja) 2019-08-08 2021-02-11 小野薬品工業株式会社 二重特異性タンパク質
US20210047425A1 (en) 2019-08-12 2021-02-18 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
JP2022544760A (ja) 2019-08-15 2022-10-21 ヤンセン バイオテツク，インコーポレーテツド 改善された単鎖可変断片のための材料及び方法
CN114340675A (zh) 2019-09-12 2022-04-12 豪夫迈·罗氏有限公司 治疗狼疮性肾炎的组合物和方法
US20220348651A1 (en) 2019-09-18 2022-11-03 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
PE20221906A1 (es) 2019-09-18 2022-12-23 Genentech Inc Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecificos anti-klk5/klk7 y metodos de uso
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
CR20220149A (es) 2019-09-20 2022-05-23 Genentech Inc Dosis para anticuerpos anti-triptasa
US20220281997A1 (en) 2019-09-27 2022-09-08 Nanjing GenScript Biotech Co., Ltd. Anti-VHH Domain Antibodies and Use Thereof
JP2022548978A (ja) 2019-09-27 2022-11-22 ジェネンテック， インコーポレイテッド 薬抗ｔｉｇｉｔ及び抗ｐｄ－ｌ１アンタゴニスト抗体を用いた処置のための投薬
EP4034561A2 (de) 2019-09-27 2022-08-03 Starkage Therapeutics Mit seneszenten zellen assoziierte antigen-bindende domänen, antikörper und chimäre antigenrezeptoren damit sowie deren verwendungen
JP2022550325A (ja) 2019-09-27 2022-12-01 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 抗ミュラー管抑制物質抗体およびその使用
WO2021058729A1 (en) 2019-09-27 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
WO2021059075A1 (en) 2019-09-27 2021-04-01 Janssen Biotech, Inc. Anti-ceacam antibodies and uses thereof
JP2022550243A (ja) 2019-09-30 2022-12-01 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド 抗ｐｄ－１抗体及びその使用
US20240058466A1 (en) 2019-10-04 2024-02-22 TAE Life Sciences Antibody Compositions Comprising Fc Mutations and Site-Specific Conjugation Properties For Use In Treating Cancer, Immunological Disorders, and Methods Thereof
JP7413519B2 (ja) 2019-10-18 2024-01-15 ジェネンテック， インコーポレイテッド びまん性大細胞型ｂ細胞リンパ腫を処置するための抗ｃｄ７９ｂ免疫抱合体の使用方法
WO2021091815A1 (en) 2019-11-04 2021-05-14 Seagen Inc. Anti-cd30 antibody-drug conjugates and their use for the treatment of hiv infection
IL292458A (en) 2019-11-06 2022-06-01 Genentech Inc Diagnostic and treatment methods for the treatment of hematological cancer
EP4055051A1 (de) 2019-11-07 2022-09-14 Genmab A/S Verfahren zur behandlung von krebs mit einer kombination aus einem anti-pd-1-antikörper und einem antikörper-wirkstoff-konjugat gegen den gewebefaktor
TW202131954A (zh) 2019-11-07 2021-09-01 丹麥商珍美寶股份有限公司 利用鉑類劑與抗組織因子抗體－藥物共軛體之組合來治療癌症之方法
WO2021094508A1 (en) 2019-11-15 2021-05-20 F. Hoffmann-La Roche Ag Prevention of visible particle formation in aqueous protein solutions
MX2022005980A (es) 2019-11-18 2022-09-07 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos.
JP2023502712A (ja) 2019-11-21 2023-01-25 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） 抗ｐｄ－１／ｉｌ－１５免疫サイトカインによる新しいｐｄ－１標的免疫療法
US20230037414A1 (en) 2019-11-22 2023-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale Inhibitors of adrenomedullin for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
WO2021115240A1 (zh) 2019-12-13 2021-06-17 四川科伦博泰生物医药股份有限公司 抗tslp抗体及其用途
TW202136303A (zh) 2019-12-13 2021-10-01 美商阿列克特有限責任公司 抗mertk抗體及其使用方法
AU2020403145A1 (en) 2019-12-13 2022-07-07 Genentech, Inc. Anti-Ly6G6D antibodies and methods of use
US20210230278A1 (en) 2019-12-18 2021-07-29 Hoffmann-La Roche Inc. Antibodies binding to HLA-A2/MAGE-A4
EP4077376A2 (de) 2019-12-19 2022-10-26 Quidel Corporation Monoklonale antikörperfusionen
AU2019479791A1 (en) 2019-12-27 2022-07-14 Chugai Seiyaku Kabushiki Kaisha Anti-CTLA-4 antibody and use thereof
CN110818795B (zh) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
WO2021194481A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2022050954A1 (en) 2020-09-04 2022-03-10 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
EP4096708A1 (de) 2020-01-31 2022-12-07 Genentech, Inc. Verfahren zur induktion neoepitopspezifischer t-zellen mit einem pd-1-achsenbindenden antagonisten und einem rna-impfstoff
AU2021220887A1 (en) 2020-02-10 2022-09-29 Shanghai Escugen Biotechnology Co., Ltd. CLDN18.2 antibody and use thereof
CA3167349A1 (en) 2020-02-10 2021-08-19 Qing Zhou Claudin 18.2 antibody and use thereof
TW202140012A (zh) 2020-02-12 2021-11-01 比利時商健生藥品公司 用於治療尿路上皮癌的ｆｇｆｒ酪胺酸激酶抑制劑和抗ｐｄ１藥劑
TW202144395A (zh) 2020-02-12 2021-12-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
WO2021163064A2 (en) 2020-02-14 2021-08-19 Jounce Therapeutics, Inc. Antibodies and fusion proteins that bind to ccr8 and uses thereof
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
CN115066440A (zh) 2020-02-28 2022-09-16 上海复宏汉霖生物技术股份有限公司 抗cd137构建体及其用途
CA3169910A1 (en) 2020-02-28 2021-09-02 Shanghai Henlius Biotech, Inc. Anti-cd137 constructs, multispecific antibody and uses thereof
IL296256A (en) 2020-03-13 2022-11-01 Genentech Inc Antibodies against interleukin-33 and uses thereof
MX2022011320A (es) 2020-03-13 2022-12-08 Janssen Biotech Inc Materiales y métodos para la unión de lectina tipo ig de unión a ácido siálico.
CN117510630A (zh) 2020-03-19 2024-02-06 基因泰克公司 同种型选择性抗TGF-β抗体及使用方法
WO2021194913A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Tie2-binding agents and methods of use
EP4127153A2 (de) 2020-03-26 2023-02-08 Genentech, Inc. Modifizierte säugetierzellen mit reduzierten wirtszellproteinen
EP4126937A1 (de) 2020-03-31 2023-02-08 Alector LLC Anti-mertk-antikörper und verfahren zur verwendung davon
CA3170570A1 (en) 2020-04-01 2021-10-07 James J. KOBIE Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
WO2021202959A1 (en) 2020-04-03 2021-10-07 Genentech, Inc. Therapeutic and diagnostic methods for cancer
US20230192795A1 (en) 2020-04-15 2023-06-22 Hoffmann-La Roche Inc. Immunoconjugates
WO2021214277A1 (en) 2020-04-24 2021-10-28 F. Hoffmann-La Roche Ag Enzyme and pathway modulation with sulfhydryl compounds and their derivatives
IL297541A (en) 2020-04-24 2022-12-01 Genentech Inc Methods for using anti-cd79b immunoconjugates
SG11202112792WA (en) 2020-04-28 2021-12-30 Univ Rockefeller Neutralizing anti-sars-cov-2 antibodies and methods of use thereof
WO2021222167A1 (en) 2020-04-28 2021-11-04 Genentech, Inc. Methods and compositions for non-small cell lung cancer immunotherapy
CN116096758A (zh) 2020-05-01 2023-05-09 诺华股份有限公司 工程化免疫球蛋白
CN115461363A (zh) 2020-05-01 2022-12-09 诺华股份有限公司 免疫球蛋白变体
EP4146283A1 (de) 2020-05-03 2023-03-15 Levena (Suzhou) Biopharma Co., Ltd. Antikörper-wirkstoff-konjugate (adcs) mit einem anti-trop-2-antikörper, zusammensetzungen mit solchen adcs sowie verfahren zur herstellung und verwendung davon
JP2023525053A (ja) 2020-05-12 2023-06-14 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） 皮膚ｔ細胞リンパ腫及びｔｆｈ由来リンパ腫を処置する新しい方法
CA3183102A1 (en) 2020-05-12 2021-11-18 Biotheus Inc. Anti-cd73 antibody and use thereof
EP4149974A1 (de) 2020-05-13 2023-03-22 Institut National de la Santé et de la Recherche Médicale (INSERM) Rekombinante proteine mit ox40-aktivierenden eigenschaften
EP4149421A1 (de) 2020-05-15 2023-03-22 F. Hoffmann-La Roche AG Verhinderung der sichtbaren partikelbildung in parenteralen proteinlösungen
MX2022014332A (es) 2020-05-15 2022-12-13 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Conjugado anticuerpo-farmaco, metodo de preparacion del mismo y uso del mismo.
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
CN115605185A (zh) 2020-05-19 2023-01-13 豪夫迈·罗氏有限公司（Ch） 螯合剂用于防止胃肠外蛋白质溶液中形成可见颗粒的用途
MX2022014943A (es) 2020-05-26 2023-03-08 Inst Nat Sante Rech Med Polipéptidos de coronavirus 2 causante del síndrome respiratorio agudo severo (sars-cov-2) y usos de los mismos para propositos de vacuna.
CR20220594A (es) 2020-05-27 2023-01-17 Janssen Biotech Inc Proteins comprising cd3 antigen binding domains and uses thereof
AU2021281417A1 (en) 2020-05-29 2022-12-08 23Andme, Inc. Anti-CD200R1 antibodies and methods of use thereof
IL298735A (en) 2020-06-02 2023-02-01 Dynamicure Biotechnology Llc Anti-CD93 constructs and their uses
CN116529260A (zh) 2020-06-02 2023-08-01 当康生物技术有限责任公司 抗cd93构建体及其用途
AR122569A1 (es) 2020-06-08 2022-09-21 Hoffmann La Roche Anticuerpos anti-vhb y métodos de uso
GB202008860D0 (en) 2020-06-11 2020-07-29 Univ Oxford Innovation Ltd BTLA antibodies
WO2021252977A1 (en) 2020-06-12 2021-12-16 Genentech, Inc. Methods and compositions for cancer immunotherapy
KR20230025691A (ko) 2020-06-16 2023-02-22 제넨테크, 인크. 삼중 음성 유방암을 치료하기 위한 방법과 조성물
KR20230024368A (ko) 2020-06-18 2023-02-20 제넨테크, 인크. 항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료
WO2021259880A1 (en) 2020-06-22 2021-12-30 Almirall, S.A. Anti-il-36 antibodies and methods of use thereof
JP2023533217A (ja) 2020-06-24 2023-08-02 ジェネンテック， インコーポレイテッド アポトーシス耐性細胞株
JP2023541216A (ja) * 2020-06-25 2023-09-29 ヒューマブ カンパニー リミテッド ヘテロ接合型トランスジェニック動物
AU2021299947A1 (en) 2020-06-29 2022-12-22 Genmab A/S Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
JP2023532764A (ja) 2020-07-07 2023-07-31 エフ． ホフマン－ラ ロシュ アーゲー 治療用タンパク質製剤の安定剤としての代替界面活性剤
TW202216761A (zh) 2020-07-16 2022-05-01 瑞士商諾華公司 抗β細胞素抗體、其片段及多特異性結合分子
PE20231300A1 (es) 2020-07-17 2023-08-24 Genentech Inc Anticuerpos anti-notch2 y metodos de uso
MX2023000888A (es) 2020-07-21 2023-02-22 Genentech Inc Inductores quimicos de degradacion conjugados con anticuerpo de brm y metodos de estos.
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
AR123083A1 (es) 2020-07-29 2022-10-26 Janssen Biotech Inc Proteínas que comprenden dominios de unión al antígeno hla-g y sus usos
CA3190328A1 (en) 2020-07-29 2022-02-03 Dynamicure Biotechnology Llc Anti-cd93 constructs and uses thereof
CN116419747A (zh) 2020-08-07 2023-07-11 福蒂斯治疗公司 靶向cd46的免疫偶联物及其使用方法
CA3192344A1 (en) 2020-08-28 2022-03-03 Genentech, Inc. Crispr/cas9 multiplex knockout of host cell proteins
WO2022053715A1 (en) 2020-09-14 2022-03-17 Ichnos Sciences SA Antibodies that bind to il1rap and uses thereof
CN116406291A (zh) 2020-10-05 2023-07-07 基因泰克公司 用抗fcrh5/抗cd3双特异性抗体进行治疗的给药
AR123767A1 (es) 2020-10-13 2023-01-11 Janssen Biotech Inc Inmunidad mediada por células t mediante bioingeniería, materiales y otros métodos para modular el cúmulo de diferenciación iv y/o viii
EP4232040A1 (de) 2020-10-20 2023-08-30 F. Hoffmann-La Roche AG Kombinationstherapie aus pd-1-achsenbindenden antagonisten und lrrk2-inhibitoren
TW202233672A (zh) 2020-10-22 2022-09-01 美商健生生物科技公司 包括類δ配體３（ＤＬＬ３）抗原結合區之蛋白質及其用途
WO2022093981A1 (en) 2020-10-28 2022-05-05 Genentech, Inc. Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
AU2021374594A1 (en) 2020-11-04 2023-06-01 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
CA3196539A1 (en) 2020-11-04 2022-05-12 Chi-Chung Li Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
CA3196076A1 (en) 2020-11-04 2022-05-12 Chi-Chung Li Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
WO2022098870A1 (en) 2020-11-04 2022-05-12 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies
CN116472288A (zh) 2020-11-06 2023-07-21 诺华股份有限公司 抗体Fc变体
CA3200878A1 (en) 2020-11-12 2022-05-19 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies conjugated or fused to the receptor-binding domain of the sars-cov-2 spike protein and uses thereof for vaccine purposes
US20240010734A1 (en) * 2020-11-13 2024-01-11 Sab, Llc Ungulate-derived polyclonal immunoglobulin specific for egfr and uses thereof
PE20231556A1 (es) 2020-11-16 2023-10-03 Hoffmann La Roche Glucoformas de fab ricas en manosa
KR20230110274A (ko) 2020-11-17 2023-07-21 씨젠 인크. 투카티닙 및 항-pd-1/항-pd-l1 항체의 조합으로 암을 치료하는 방법
AR124123A1 (es) 2020-11-20 2023-02-15 Inst Nat Sante Rech Med Anticuerpos anti-cd25
JP2024504547A (ja) 2020-11-20 2024-02-01 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 抗ｃｄ２５抗体
WO2022120352A1 (en) 2020-12-02 2022-06-09 Alector Llc Methods of use of anti-sortilin antibodies
EP4260872A1 (de) 2020-12-09 2023-10-18 National University Corporation Tokyo Medical and Dental University Mittel zur prävention oder behandlung von frontotemporaler lobar-degeneration
WO2022130182A1 (en) 2020-12-14 2022-06-23 Novartis Ag Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
JP7326584B2 (ja) 2020-12-17 2023-08-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｈｌａ－ｇ抗体及びその使用
WO2022132904A1 (en) 2020-12-17 2022-06-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies targeting sars-cov-2
CN116940373A (zh) 2020-12-23 2023-10-24 国家健康科学研究所 基于将momp vs4抗原靶向至抗原呈递细胞的衣原体疫苗
JP2024501739A (ja) 2020-12-31 2024-01-15 諾納生物（蘇州）有限公司 ヒトｌｉｆｒ抗原結合タンパク質、その製造方法及び応用
WO2022148853A1 (en) 2021-01-11 2022-07-14 F. Hoffmann-La Roche Ag Immunoconjugates
US20240115720A1 (en) 2021-01-13 2024-04-11 Memorial Sloan Kettering Cancer Center Antibody-pyrrolobenzodiazepine derivative conjugate
JP2024503658A (ja) 2021-01-13 2024-01-26 メモリアル スローン－ケタリング キャンサー センター 抗ｄｌｌ３抗体－薬物コンジュゲート
EP4277926A1 (de) 2021-01-15 2023-11-22 The Rockefeller University Neutralisierende anti-sars-cov-2-antikörper
US20240059789A1 (en) 2021-01-28 2024-02-22 Janssen Biotech, Inc. Psma binding proteins and uses thereof
KR20230135620A (ko) 2021-01-29 2023-09-25 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 클라미디아 트라코마티스 항원 폴리펩타이드 및 백신목적을 위한 이의 용도
IL304955A (en) 2021-02-09 2023-10-01 Us Health Antibodies targeting the spike protein of a coronavirus
CA3210753A1 (en) 2021-02-09 2022-08-18 University Of Georgia Research Foundation, Inc. Human monoclonal antibodies against pneumococcal antigens
WO2022184082A1 (en) 2021-03-03 2022-09-09 Sorrento Therapeutics, Inc. Antibody-drug conjugates comprising an anti-bcma antibody
JP2024509191A (ja) 2021-03-05 2024-02-29 ダイナミキュア バイオテクノロジー エルエルシー 抗ｖｉｓｔａ構築物およびその使用
KR20230154317A (ko) 2021-03-05 2023-11-07 상하이 젠베이스 바이오테크놀로지 씨오., 엘티디. 항-cldn6 항체 및 이의 용도
US20240018237A1 (en) 2021-03-09 2024-01-18 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Ror1 binding protein and use thereof
WO2022192647A1 (en) 2021-03-12 2022-09-15 Genentech, Inc. Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
WO2022198192A1 (en) 2021-03-15 2022-09-22 Genentech, Inc. Compositions and methods of treating lupus nephritis
WO2022197947A1 (en) 2021-03-18 2022-09-22 Alector Llc Anti-tmem106b antibodies and methods of use thereof
WO2022197877A1 (en) 2021-03-19 2022-09-22 Genentech, Inc. Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
WO2022204274A1 (en) 2021-03-23 2022-09-29 Alector Llc Anti-tmem106b antibodies for treating and preventing coronavirus infections
AU2022244453A1 (en) 2021-03-24 2023-11-09 Janssen Biotech, Inc. Antibody targeting cd22 and cd79b
EP4314056A1 (de) 2021-03-24 2024-02-07 Janssen Biotech, Inc. Proteine mit cd3-antigenbindenden domänen und verwendungen davon
EP4314049A1 (de) 2021-03-25 2024-02-07 Dynamicure Biotechnology LLC Anti-igfbp7-konstrukte und verwendungen davon
TW202304506A (zh) 2021-03-25 2023-02-01 日商安斯泰來製藥公司 涉及抗claudin 18.2抗體的組合治療以治療癌症
AU2022244125A1 (en) 2021-03-26 2023-10-19 BioNTech SE Combination therapy with an anti-ca19-9 antibody and folfirinox in the treatment of cancer
AR125344A1 (es) 2021-04-15 2023-07-05 Chugai Pharmaceutical Co Ltd Anticuerpo anti-c1s
JP2024514222A (ja) 2021-04-19 2024-03-28 ジェネンテック， インコーポレイテッド 改変された哺乳動物細胞
AU2021443863A1 (en) 2021-04-30 2023-10-26 F. Hoffmann-La Roche Ag Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
KR20240005691A (ko) 2021-04-30 2024-01-12 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이적 항체 및 항-cd79b 항체 약물 접합체를 이용한 병용 치료를 위한 투약
EP4334343A2 (de) 2021-05-06 2024-03-13 The Rockefeller University Neutralisierende anti-sars-cov-2-antikörper und verfahren zur verwendung davon
CA3218170A1 (en) 2021-05-12 2022-11-17 Jamie Harue HIRATA Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
WO2022246259A1 (en) 2021-05-21 2022-11-24 Genentech, Inc. Modified cells for the production of a recombinant product of interest
CN113278071B (zh) 2021-05-27 2021-12-21 江苏荃信生物医药股份有限公司 抗人干扰素α受体1单克隆抗体及其应用
TW202306994A (zh) 2021-06-04 2023-02-16 日商中外製藥股份有限公司 抗ddr2抗體及其用途
IL308015A (en) 2021-06-09 2023-12-01 Hoffmann La Roche A combination of a specific BRAF inhibitor (paradox breaker) and a PD-1 spindle-binding antagonist for use in cancer treatment
EP4355786A1 (de) 2021-06-16 2024-04-24 Alector LLC Bispezifische anti-mertk- und anti-pdl1-antikörper und verfahren zur verwendung davon
EP4355783A1 (de) 2021-06-16 2024-04-24 Alector LLC Monovalente anti-mertk-antikörper und verfahren zur verwendung davon
EP4355785A1 (de) 2021-06-17 2024-04-24 Amberstone Biosciences, Inc. Anti-cd3-konstrukte und verwendungen davon
IL308959A (en) 2021-06-18 2024-01-01 Nammi Therapeutics Inc Fusion protein composition(s) containing masked type I interferons (IFNalpha and IFNbeta) for use in cancer therapy and methods thereof
EP4361176A1 (de) 2021-06-25 2024-05-01 Chugai Seiyaku Kabushiki Kaisha Verwendung eines anti-ctla-4-antikörpers
EP4361273A1 (de) 2021-06-25 2024-05-01 Chugai Seiyaku Kabushiki Kaisha Anti-ctla-4-antikörper
IL309856A (en) 2021-07-14 2024-02-01 Genentech Inc Antibodies anti-C-C motif receptor 8 (CCR8) and methods of use
WO2023004386A1 (en) 2021-07-22 2023-01-26 Genentech, Inc. Brain targeting compositions and methods of use thereof
WO2023001884A1 (en) 2021-07-22 2023-01-26 F. Hoffmann-La Roche Ag Heterodimeric fc domain antibodies
CN117794953A (zh) 2021-08-03 2024-03-29 豪夫迈·罗氏有限公司 双特异性抗体及使用方法
WO2023019239A1 (en) 2021-08-13 2023-02-16 Genentech, Inc. Dosing for anti-tryptase antibodies
TW202325727A (zh) 2021-08-30 2023-07-01 美商建南德克公司 抗聚泛素多特異性抗體
CN113683694B (zh) 2021-09-03 2022-05-13 江苏荃信生物医药股份有限公司 一种抗人tslp单克隆抗体及其应用
CN113603775B (zh) 2021-09-03 2022-05-20 江苏荃信生物医药股份有限公司 抗人白介素-33单克隆抗体及其应用
WO2023046322A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceutica Nv Proteins comprising cd20 binding domains, and uses thereof
WO2023056403A1 (en) 2021-09-30 2023-04-06 Genentech, Inc. Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
CA3233924A1 (en) 2021-10-08 2023-04-13 Kengo ARAI Method for preparing prefilled syringe formulation
WO2023062048A1 (en) 2021-10-14 2023-04-20 F. Hoffmann-La Roche Ag Alternative pd1-il7v immunoconjugates for the treatment of cancer
WO2023062050A1 (en) 2021-10-14 2023-04-20 F. Hoffmann-La Roche Ag New interleukin-7 immunoconjugates
WO2023069919A1 (en) 2021-10-19 2023-04-27 Alector Llc Anti-cd300lb antibodies and methods of use thereof
WO2023076989A1 (en) 2021-10-29 2023-05-04 Seagen Inc. Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody-drug conjugate
WO2023086807A1 (en) 2021-11-10 2023-05-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
TW202337494A (zh) 2021-11-16 2023-10-01 美商建南德克公司 用莫蘇妥珠單抗治療全身性紅斑狼瘡（ｓｌｅ）之方法及組成物
WO2023088968A1 (en) 2021-11-17 2023-05-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Universal sarbecovirus vaccines
WO2023089587A1 (en) 2021-11-22 2023-05-25 Janssen Biotech, Inc. Compositions comprising enhanced multispecific binding agents for an immune response
TW202340251A (zh) 2022-01-19 2023-10-16 美商建南德克公司 抗ｎｏｔｃｈ２抗體及結合物及其使用方法
WO2023147399A1 (en) 2022-01-27 2023-08-03 The Rockefeller University Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
WO2023152581A1 (en) 2022-02-09 2023-08-17 Janssen Biotech, Inc. Method of treating cancer with psmaxcd3 antibody
WO2023154824A1 (en) 2022-02-10 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that broadly target coronaviruses
WO2023170207A1 (en) 2022-03-09 2023-09-14 Alderaan Biotechnology Anti-cd160 transmembrane isoform antibodies
WO2023173026A1 (en) 2022-03-10 2023-09-14 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
TW202346365A (zh) 2022-03-23 2023-12-01 瑞士商赫孚孟拉羅股份公司 抗ｃｄ２０／抗ｃｄ３雙特異性抗體及化學療法之組合治療
WO2023191816A1 (en) 2022-04-01 2023-10-05 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023198727A1 (en) 2022-04-13 2023-10-19 F. Hoffmann-La Roche Ag Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
US20230357381A1 (en) 2022-04-26 2023-11-09 Novartis Ag Multispecific antibodies targeting il-13 and il-18
WO2023215737A1 (en) 2022-05-03 2023-11-09 Genentech, Inc. Anti-ly6e antibodies, immunoconjugates, and uses thereof
WO2023213960A1 (en) 2022-05-06 2023-11-09 Genmab A/S Methods of treating cancer with anti-tissue factor antibody-drug conjugates
WO2023219613A1 (en) 2022-05-11 2023-11-16 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023235699A1 (en) 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof
WO2023240058A2 (en) 2022-06-07 2023-12-14 Genentech, Inc. Prognostic and therapeutic methods for cancer
CN114875074B (zh) * 2022-06-17 2023-10-24 吉林大学 提高多克隆兔抗体产生的方法
WO2024006961A1 (en) 2022-07-01 2024-01-04 Neoleukin Therapeutics, Inc. Neo-2/15 variants and uses thereof for preferentially stimulating t-regulatory cells
WO2024015897A1 (en) 2022-07-13 2024-01-18 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024020432A1 (en) 2022-07-19 2024-01-25 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024020564A1 (en) 2022-07-22 2024-01-25 Genentech, Inc. Anti-steap1 antigen-binding molecules and uses thereof
WO2024026471A1 (en) 2022-07-29 2024-02-01 Alector Llc Cd98hc antigen-binding domains and uses therefor
WO2024026447A1 (en) 2022-07-29 2024-02-01 Alector Llc Anti-gpnmb antibodies and methods of use thereof
WO2024026472A2 (en) 2022-07-29 2024-02-01 Alector Llc Transferrin receptor antigen-binding domains and uses therefor
WO2024030829A1 (en) 2022-08-01 2024-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
WO2024049949A1 (en) 2022-09-01 2024-03-07 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
WO2024054929A1 (en) 2022-09-07 2024-03-14 Dynamicure Biotechnology Llc Anti-vista constructs and uses thereof
WO2024054822A1 (en) 2022-09-07 2024-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Engineered sars-cov-2 antibodies with increased neutralization breadth
WO2024062019A1 (en) 2022-09-21 2024-03-28 Synabs Anti-ccr8 antibodies and uses thereof
WO2024074571A1 (en) 2022-10-05 2024-04-11 Institut National de la Santé et de la Recherche Médicale Dc-targeting vaccine against nipah virus infection
WO2024077239A1 (en) 2022-10-07 2024-04-11 Genentech, Inc. Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1293460C (en) 1985-10-07 1991-12-24 Brian Lee Sauer Site-specific recombination of dna in yeast
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5652338A (en) * 1988-03-16 1997-07-29 The United States Of America As Represented By The Department Of Health And Human Services Neutrophil chemotactic factor
US5270201A (en) 1988-03-24 1993-12-14 The General Hospital Corporation Artificial chromosome vector
WO1989009219A1 (en) 1988-03-24 1989-10-05 The General Hospital Corporation Artificial chromosome vector
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) * 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
GB8909218D0 (en) 1989-04-22 1989-06-07 Medical Res Council Improvements in or relating to enhancers
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
DE69034263D1 (de) * 1989-07-25 2009-04-02 Cell Genesys Inc Homologe Rekombination für universelle Donorzellen und chimerische Säugetierzellen
US6673986B1 (en) * 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
JP3068180B2 (ja) * 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
CA2084774A1 (en) 1990-06-12 1991-12-13 Allan Bradley Method for homologous recombination in animal and plant cells
US5614396A (en) 1990-06-14 1997-03-25 Baylor College Of Medicine Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
ATE185601T1 (de) 1990-07-10 1999-10-15 Cambridge Antibody Tech Verfahren zur herstellung von spezifischen bindungspaargliedern
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) * 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) * 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
DE69333082T2 (de) 1992-02-11 2004-05-06 Cell Genesys, Inc., Foster City Erzielen von homozygotem durch zielgerichtete genetische ereignisse
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
WO1995023865A1 (en) * 1994-03-03 1995-09-08 Genentech, Inc. Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders
GB9410446D0 (en) 1994-05-25 1994-07-13 Cancer Res Campaign Tech Novel chromosome fragment
KR100261941B1 (ko) 1994-07-13 2000-07-15 나가야마 오사무 사람의 인터루킨-8에 대한 재구성 사람항체
US5543319A (en) 1995-03-31 1996-08-06 Fred Hutchinson Cancer Research Center Recombination-proficient avian/mammalian microcell hybrids
EP0843961B1 (de) 1995-08-29 2007-01-24 Kirin Beer Kabushiki Kaisha Chimäres tier und methode zu dessen herstellung
US6632976B1 (en) * 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
US6025155A (en) 1996-04-10 2000-02-15 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
AU3507297A (en) 1996-06-26 1998-01-14 Baylor College Of Medicine Chromosomal rearrangement by insertion of two recombination substrates
EP1707051B1 (de) 1997-02-28 2010-01-13 Kyowa Hakko Kirin Co., Ltd. Humanes Chromosomfragment und ein Vektor, der dies enthält
AU7057398A (en) 1997-04-11 1998-11-11 Imperial College Of Science, Technology And Medicine Chromosome transfer (xmmct) to es cells, induced during the exposure of microcells to radiation
GB9711167D0 (en) 1997-05-31 1997-07-23 Babraham The Inst Telomere-associated chromosome fragmentation
TWI255853B (en) 1998-08-21 2006-06-01 Kirin Brewery Method for modifying chromosomes
US6833268B1 (en) * 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
AU6476000A (en) 1999-08-13 2001-03-13 Kirin Beer Kabushiki Kaisha Mouse having human cytochrome p450 transferred therein
JP2001231403A (ja) 2000-02-18 2001-08-28 Kirin Brewery Co Ltd 改変された外来染色体あるいはその断片を保持する非ヒト動物
US7041870B2 (en) * 2000-11-30 2006-05-09 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
AU2002309063B8 (en) 2001-05-11 2008-04-24 Kyowa Kirin Co., Ltd. Artificial human chromosome containing human antibody lambda light chain gene
CA2847885C (en) 2001-11-30 2022-03-22 Amgen Fremont Inc. Transgenic animals bearing human ig.lambda. light chain genes

Also Published As

Publication number Publication date
WO2002043478A8 (en) 2004-05-27
EP1916303A1 (de) 2008-04-30
CA2430013A1 (en) 2002-06-06
DE60131456T2 (de) 2008-07-10
MXPA03004793A (es) 2004-12-03
CN1487996B (zh) 2010-06-16
JP3523245B1 (ja) 2004-04-26
EP1354034B1 (de) 2007-11-14
JP2004515230A (ja) 2004-05-27
EP1354034B8 (de) 2008-06-18
EP1916303B1 (de) 2013-02-27
US8835712B2 (en) 2014-09-16
US20110003319A1 (en) 2011-01-06
AU3942202A (en) 2002-06-11
US7816578B2 (en) 2010-10-19
PT1354034E (pt) 2008-02-28
ES2405944T3 (es) 2013-06-04
DK1354034T3 (da) 2008-03-25
AU2002239422B2 (en) 2006-12-07
US20060037093A1 (en) 2006-02-16
KR100857943B1 (ko) 2008-09-09
WO2002043478A2 (en) 2002-06-06
US20160324131A1 (en) 2016-11-10
TWI313299B (en) 2009-08-11
CA2430013C (en) 2011-11-22
EP1354034A2 (de) 2003-10-22
US7041870B2 (en) 2006-05-09
US20060026698A1 (en) 2006-02-02
US20140380515A1 (en) 2014-12-25
IL155977A0 (en) 2003-12-23
WO2002043478A3 (en) 2003-08-28
DE60131456D1 (de) 2007-12-27
IL155977A (en) 2009-06-15
CN101940189A (zh) 2011-01-12
US7576258B2 (en) 2009-08-18
US20020199213A1 (en) 2002-12-26
US10076103B2 (en) 2018-09-18
KR20030074634A (ko) 2003-09-19
US9426970B2 (en) 2016-08-30
HK1064708A1 (en) 2005-02-04
CN1487996A (zh) 2004-04-07
ES2295228T3 (es) 2008-04-16

Similar Documents

Publication Publication Date Title
ATE378403T1 (de) Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern
IL189629A0 (en) Compositions containing human ctla-4 antibodies
DK0758904T3 (da) Fremgangsmåder og sammensætninger til behandling af glomerulonephritis
DK0854917T3 (da) Transgene ikke-humane dyr, som kan producere heterologe antistoffer
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
ATE481108T1 (de) Verwendung von bioadhaesiven und adjuvantien für die mukosale anwendung von antigenen
DK1252184T3 (da) Human C1-inhibitor produceret i mælk af transgene dyr
NO20041917L (no) Spesifikke midler som binder humant angiopoietin-2
ATE415979T1 (de) Behandlung mit anti-erbb2 antikörpern
DE69637481D1 (de) Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
ATE554107T1 (de) Als therapeutika geeignete monovalente antikörperfragmente
ATE425761T1 (de) Agarwood aus kulturmassigem anbau
DE50203814D1 (de) Silikonkautschukzusammensetzung zur Herstellung von Kabeln bzw. Profilen
ATE452655T1 (de) Verwendung von l-polynukleotiden zur diagnostischen bilderzeugung
ES2190908T1 (es) Composicion cosmetica que comprende seroalbumina humana obtenida de animales transgenicos no humanos.
DE602004028592D1 (de) Gegen clostridium difficile gerichtete antikörper
DE60239842D1 (de) Verfahren zur Herstellung von 10,11-dihydro-10-oxo-5h-dibenzoÄb,fÜazepin-5-carboxamid
DE60332111D1 (de) Transgene huftiere, die zur produktion von menschlichen antikörpern fähig sind
DE60139249D1 (de) Methode zur herstellung von transgene säugetiere mittels transposons
DE60120425D1 (de) Verfahren zur herstellung von klonierten vögeln
DE60108105D1 (de) Verfahren zur Herstellung von 5-substituierten Isobenzofuranen
ATE343387T1 (de) S-methyl-dihydro-ziprasidon zur behandlung von augenerkrankungen.
DE60230097D1 (de) Verfahren zur herstellung von 1,5-diaminonaphthalinen
DE60208365D1 (de) Verwendung von pyridoindolonderivaten zur herstellung von antikrebsmitteln
ATE414154T1 (de) Moraxella (branhamella) catarrhalis antigene

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1354034

Country of ref document: EP

EEIH Change in the person of patent owner
EEIH Change in the person of patent owner